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Abstract 
Vpu has been shown to possess two distinct roles in the pathogenesis of HIV.  
First, Vpu has been shown to down-regulate the expression of CD4 molecules at the 
plasma membrane of infected cells by targeting CD4 molecules for degradation in the 
endoplasmic reticulum.  Second, Vpu promotes viral egress in specific cell lines termed 
non-permissive cells by mechanism that remain relatively unclear.  
Therefore, experiments were conducted in order to identify cellular factors 
involved in the Vpu-dependent phenotype.  Using full-length Vpu as bait in yeast two-
hybrid experiments, several candidate cellular factors were identified.  One protein, 
SNAPIN, was identified as a cellular factor putatively involved in the Vpu-dependent 
phenotype.  Further experiments determined that not only do SNAPIN and Vpu interact, 
but that Vpu also leads to the degradation of SNAPIN by both proteasomal and lysosomal 
degradation pathways. 
Over-expression of SNAPIN in cell lines that do not normally require Vpu 
expression for viral production resulted in a Vpu-dependent phenotype.  While over-
expression of SNAPIN in otherwise permissive cell lines significantly reduced Vpu-
deficient virus production, wild type levels remained relatively constant. Importantly, no 
defective viral structural protein production was observed; however, intracellular p24/p55 
did not accumulate suggesting that in SNAPIN expressing cells, Gag is also targeted for 
degradation.  
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In addition, the reduction of SNAPIN expression in non-permissive cell lines 
significantly increased viral titers in supernatants. Of particular interest, even in cells 
expressing Bst-2 (a previously identified cellular factor involved in the Vpu-phenotype), 
siRNA mediated knockdown of SNAPIN led to increased viral titers.  In addition, the co-
transfection of siRNAs targeting both SNAPIN and Bst-2 resulted in an additive effect, in 
which Vpu-deficient viral titers were nearly equivalent to wild-type titers.  Surprisingly, 
siRNA-mediated knockdown of SNAPIN in Jurkat cells was sufficient to overcome any 
restriction in viral egress imposed by the deletion of Vpu.  Conversely, siRNA targeting 
Bst-2 had little or no effect on viral titers in Jurkat cells regardless of whether it was 
transfected alone or in combination with siRNAs targeting SNAPIN.   
These experiments provide evidence of an alternate cellular restriction mechanism 
involved in viral egress that is countered by the HIV-1 accessory protein, Vpu.  In 
addition, this research may provide further insight into the complex cellular networks 
involved in the trafficking of Gag through cellular endosomal pathways.   
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Chapter I 
Introduction 
1.1 The Global impact of HIV/AIDS 
Human immunodeficiency virus (HIV) was identified as the causative agent of 
Acquired Immunodeficiency Disease Syndrome (AIDS) in the early eighties (1).  
Homosexual men in New York and California suddenly began developing a syndrome of 
diseases that included unusual opportunistic infections and rare cancers that responded 
poorly to conventional treatments.  Soon after, this syndrome became apparent in 
injection drug users and in patients that had received blood transfusions (1, 2).  What had 
originally been thought of as a homosexual related epidemic was affecting a much 
broader group of people that inevitably spread to all social groups.   
It is estimated that as many as 31 to 36 million people are infected with HIV-1 
worldwide and AIDS has claimed the lives of an estimated 16 million since the beginning 
of the pandemic (Figure 1.1) (2). HIV/AIDS is the fourth leading cause of death 
worldwide and the leading cause of death due to an infectious disease (1, 3).   
Approximately 2.3 million people worldwide succumbed to AIDS and AIDS-related 
opportunistic infections in 2008 alone (2).  
Given that sixty-seven percent of HIV-1 infected people live in Sub-Saharan 
Africa, economics and access to medicine are major challenges for developing and 
transitional countries in stemming the progression and spread of the disease (1-3, 9).  
Prevalence rates in excess of 30% exist in countries such as Botswana and Zimbabwe, 
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while the average life-expectancy of an AIDS patient in the seven countries most affected 
by the pandemic decreases from 67 years for a non-infected individual to 37 years (3). 
The significant impact of AIDS in Africa goes beyond victims of the disease as an 
estimated 14 million children have been left orphaned due to the loss of both parents (3). 
Ninety percent of the children living with AIDS live in Sub-Saharan Africa (1, 4).  It is 
estimated that more than half of the hospital beds in sub-Saharan Africa are occupied by 
patients with AIDS related diseases and by 2020, upwards of 30% of the general 
workforce will be lost in countries with the highest prevalence rates (3).   
HIV/AIDS, however, is not relegated to developing countries as over 1 million 
Americans have been diagnosed with HIV since the beginning of the pandemic (4, 6).  In 
2006, approximately 15,000 deaths were attributed to HIV/AIDS while 56,000 people 
become infected that year alone (4).  Considering that antiviral therapies are easily 
accessible in the USA and the intense media campaign that was waged by the US 
government and AIDS awareness groups, the number of deaths and new infections are 
staggering.  Furthermore, while a strict regimen of HAART treatment has significantly 
increased the life expectancy of HIV positive patients in developed countries, HIV still 
reduces infected individuals life expectancies by approximately one-third (6). HIV/AIDS 
still remains as one of the major challenges of modern medicine. 
Current statistics from the CDC suggest that heterosexual transmission rates are 
on the rise, contributing to approximately one-third of new HIV diagnoses since 2006.  
Male-to-male sexual transmission currently accounts for the majority of transmission 
(48%) while injection drug use is responsible for the remainder of infections (4). 
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Fortunately, the spread from mother to child during birth has decreased significantly due 
to the introduction of antiviral therapy at the time of birth (7).   
In 1987, a drug named azidothymidine (AZT) that was originally synthesized in 
1964 as a possible anticancer drug, showed promising results in clinical trials against 
HIV infection (158).  AZT was shown to lower the viral load in the blood and slow the 
progression of AIDS in HIV positive patients (158).  However, the cost of $7000 (in 
1989) for a yearly supply was a significant obstacle for those in need of the medication 
(8).  Furthermore, strains resistant to AZT began to emerge in the early 1990s leading to 
an urgent need for more antiviral drugs (8, 159).   
In 1995, the first of a new class of drugs, protease inhibitors, was approved by the 
FDA (8).  Non-nucleoside reverse transcriptase inhibitors soon followed and when taken 
in combination with other antivirals, hospitalized patients were soon able to go home.  
The discovery of antivirals changed the outlook for HIV positive patients as AIDS would 
become a manageable disease rather than a fatal one.  AIDS has become a chronic, 
treatable disease with infected people living longer healthier lives; that is, for people that 
have access and can afford the substantial cost of antiviral therapy (5).   
Clearly, the most cost effective treatment for the AIDS pandemic would be the 
development of a HIV vaccine (14).  However, little progress has been made since the 
first vaccine trial by the company AIDSvaxs in 1998.  One study recently conducted by 
Merck Pharmaceuticals revealed that its candidate vaccine may have actually led to an 
increased rate of infection due to adverse immune responses to the vaccine.  Despite all 
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the research, money and efforts of the scientific community, an effective vaccine has 
remained elusive.  
The quasispecies that soon arise after the initial infection with a founding virus, 
have made antibody-based vaccines relatively obsolete (10). Clearly, the high mutation 
rate that is a hallmark of HIV replication has made the development of broadly reactive 
antibodies with protective functions a daunting task (10, 11).  Currently, the consensus 
among the HIV vaccine field is that a vaccine that elicits both a humoral and cell-
mediated immune response must be developed to combat the AIDS epidemic. However, 
as of yet, the proper epitopes and immunogens have yet to be identified (12). 
With the lack of progress in vaccine development and the emergence of new 
antiviral drug resistant HIV strains, the need to develop additional anti-retrovirals is an 
urgent and pressing matter (13-15).  Further research into the basic and fundamental 
processes of the viral life-cycle may lead to the identification of potentially novel 
antiviral targets.  As part of this process, understanding virus-host interactions may lead 
to a greater understanding of innate cellular factors capable of restricting viral replication 
from which new therapeutic strategies may be devised.  
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Figure 1.1: Global Perspectives of HIV/AIDS (1). The global distribution of 
HIV/AIDS in the world according to UNAIDS/WHO statistics. Sixty-seven 
percent of people living with HIV/AIDS are found in Sub-Saharan Africa.  It is 
estimated that 0.6% of the world’s population is currently infected with HIV.   
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1.2 The Evolution of the HIV/AIDS Pandemic 
Recent studies, based on a complex computer model of HIV evolution, suggested 
that HIV-1 actually entered the human population as early as the 1884 to 1924 (16).  The 
earliest actual human specimen containing HIV was diagnosed in a plasma sample from 
an adult male living in what is now known as the Democratic Republic of Congo (17).   
Interestingly, the first clinical sample containing HIV in the USA was diagnosed in tissue 
samples from a teenager who died in St. Louis, Missouri in 1969 (18).  How HIV initially 
crossed the species barrier from primates to humans is a subject of intense debate.  
Researchers have concluded that Africa was the continent where transmission 
took place since monkeys from either Asia or South America have not been found to 
carry SIVs that could have started the human pandemic (19).  In 2006, a research group 
had identified a strain of SIV remarkably similar to HIV in chimpanzees, SIVcpz, in 
Cameroon (20). It has been postulated that human consumption of infected non-human 
primates in this region may have led the cross-species transmission and the beginning of 
the AIDS pandemic (21).   
Of importance, SIVcpz has since been shown to cause a disease with similar 
characteristics in chimpanzees to that observed in patients with AIDS (19).  These 
findings were somewhat surprising given that African primates are naturally infected 
with over 40 diverse SIV strains, yet unlike SIVcpz, none are thought to cause AIDS-like 
diseases in their natural hosts (19, 20, 22).  Researchers remain hopeful that the discovery 
of SIVcpz will accelerate the identification of cellular and viral determinants of disease 
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progression in both chimpanzees and humans, ultimately leading the development of 
novel therapeutics (19, 57).    
1.3 Viral Pathogenesis & Viral Replication 
Viral Pathogenesis 
 The majority of HIV-1 infections occur through sexual intercourse through the 
genital tract or rectal mucosa (23, 24).  Whether HIV-1 is transmitted in humans as a free 
or cell-associated virus is currently unknown.  SIV studies in non-human primates have 
determined that viral transmission can occur with both forms of virus (25).  However, the 
exact mechanisms by which HIV-1 crosses mucosal epitheliums remains unclear (23).  
 Approximately 80% of infectious molecular clones isolated early after infection 
have a higher efficiency for infecting CD4+ T-cells than macrophages (26). This finding 
contrasts quasispecies that arise later during the course of infection as HIV-1 strains with 
equal affinities for lymphoid and myeloid cells begin to emerge (26).  Studies in the 
macaque model have demonstrated that the first cells to become infected in the vaginal 
mucosa were found in foci of resident memory T-cells (26, 27).  The initial progeny 
produced early after infection are homogeneous with the founder virus suggesting that an 
established infection probably arises from a single foci of infected mucosal CD4+ T-cells 
(24, 27).  The early innate immune response likely contributes to the recruitment of 
additional CD4+ T-cells that are susceptible to infection (27).  
 Virus and virus-infected cells migrate through the lymphatic system where they 
come into contact with additional targets for infection in the draining lymph nodes (23).  
In addition, infection is further augmented by the trans-association of virions with 
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dendritic cells that come into contact with vulnerable CD4+ T-cell populations (28).  At 
this stage, virion dissemination occurs rapidly to other lymphoid tissue, including the gut-
associated lymphoid tissue (GALT) (29-33). It is estimated that up to 20% of CD4+ T-
cells are infected in the acute phase of the disease in the GALT while 60% of uninfected 
CD4+ T-cells die due to activation induced bystander apoptosis (32).  Although CD4+ T-
cell numbers eventually return to near normal levels in the blood, CD4+ T-cells numbers 
do not return to normal levels in the GALT (29, 31, 32).  Macrophages and memory T-
cell are important targets of HIV as they are thought to have an important role in creating 
a viral reservoir (24).   
Viral Replication 
HIV is classified as a lentivirus, and as is the case with all viruses in this genus, 
HIV attacks cells of the immune system (35).  Lentiviruses are part of the retroviridae 
family; a group of ‘slow’ viruses in the sense that they have long incubation periods 
before disease becomes apparent (35).  Lentiviruses are single stranded, positive-sense, 
enveloped RNA viruses.  As illustrated in figure 1.3, upon virion binding to the CD4 
receptor as well as co-receptors on the surface of CD4+ T-cells or macrophages, virions 
enter the cytoplasm through the process of endocytosis (36-37).   
During microtubule transport of the reverse transcription complex (RTC) to the 
nucleus, the viral single stranded RNA genome is converted to double stranded DNA by 
the viral reverse transcriptase (RT) enzyme (38, 49). The viral cDNA is then inserted into 
the host genome by the viral integrase (IN) enzyme where the proviral genome may 
remain latent for long periods of time (39).  Since the virus is integrated into the host 
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cell’s genome, all progeny cells will harbor the viral genome and can contribute to the 
overall spread of the virus throughout the host (40).   
The exact mechanisms of viral reactivation are not completely understood, 
however, several studies have defined several pathways that trigger HIV reactivation (41, 
42, 50).  Research has suggested that it is the lack of transcription factors in quiescent 
cells that leads to a state of latency as cellular activation dramatically increases viral 
production (42, 50).  Increased expression and activation of NFκB is particularly 
important for virus production (41).  
Once the cellular environment is sufficient to promote viral replication, viral 
mRNA is transcribed from the integrated provirus.  The mRNA is then spliced into 
smaller, viral mRNAs encoding the two regulatory viral proteins, Tat and Rev, which are 
required for efficient viral production (43).  At this stage, full-length genomic mRNA 
serves a dual purpose as it is translated into the structural proteins (Gag and Env) and 
packaged into assembling virions. 
The Env polyprotein (gp160) is processed through the endoplasmic reticulum and 
is transported to the Golgi complex where it is cleaved into two glycoproteins, gp41 and 
gp120 (44).  The processed Env proteins are then targeted to sites of viral particle 
assembly. Gag (p55) and Gag-Pol (p160) along with HIV genomic RNA then associate 
with the inner surface of the membrane structure containing processed Env (45).  The site 
of viral particle assembly and release is currently under intense debate and discussed 
further in this introduction and in Chapter VII.  In general, viral assembly is thought to 
occur at either the plasma membrane or in internal membrane vesicles (46, 47).  Viral 
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maturation either occurs while virions form or once virions are released from an infected 
cell by the cleavage of viral polyproteins by the viral protease (48).  The structural 
components then assemble to produce mature virions capable of infecting other cells.   
1.4 Viral Accessory genes & Cellular Restriction Factors 
 Lentiviruses, such as HIV-1, are complex retroviruses that encode several genes 
that until recently, were thought to be dispensable for viral replication (51). These genes, 
termed “accessory” genes, play a crucial role in the pathogenesis of HIV as viruses 
carrying mutations are invariably attenuated in vivo (Figure 2.2).  In contrast, the 
requirement for specific accessory genes in vitro tends to be cell-type dependent (51).  In 
this regard, cell lines in which a particular accessory gene is required for efficient viral 
replication are said to be non-permissive. Cell lines that do not show attenuation of viral 
replication in the absence of an accessory gene are termed permissive.   
HIV-1 encodes six accessory genes including two regulatory genes that are 
essential for viral replication (tat and rev) and four that appear to have a principal role in 
evading intrinsic and adaptive immune responses (nef, vif, vpu and vpr)  (43, 52).  As 
illustrated in figure 1.3, the outcome of their cumulative function is the creation of an 
environment that promotes viral persistence, replication, dissemination and transmission 
(53). At a cellular level, accessory genes enable HIV to overcome cellular blocks, known 
as restriction factors that limit viral replication at different stages of the viral life-cycle. 
 Both Nef and Vpu down-regulate cellular receptors from the plasma membrane 
by bridging specific receptors with specific degradation pathways.  Both are capable of 
down-regulating CD4 and major histocompatibility complex-1 (MHC-I), which are two 
25 
 
receptors of critical importance for initiating an adaptive immune response (53).  The 
down-regulation of these receptors from the plasma membrane of infected cells allows 
the virus to remain undetected and contributes to virion dissemination and viral 
persistence (53).   
 Interestingly, Nef mediated degradation of CD4 occurs at the plasma membrane, 
whereas Vpu-mediated degradation of CD4 occurs in the endoplasmic reticulum (54, 55).  
Nef interacts with the cytoplasmic tail of CD4 and a clathrin adapter protein complex 
(AP2) to initiate endocytosis of CD4 molecules (55).  This process ultimately ends in the 
degradation of CD4 in lysosomes.  In contrast, Vpu targets nascent CD4 molecules for 
proteasome-mediated degradation by recruiting a ubiquitin ligase complex to the 
cytoplasmic tail of CD4 in the ER (54).  The degradation of MHC-I molecules by Nef 
and Vpu occurs through similar pathways (53).  In addition to its ability to down-regulate 
receptors from the plasma membrane, Vpu has an important role in promoting viral 
egress as discussed in the following section.   
 The ability to down-regulate surface receptors and to promote viral egress has 
been linked to two distinct structural domains of Vpu (161, 162).  Vpu possesses a short 
cytoplasmic tail that through mutational analysis has been shown to be required for 
targeting surface receptors for degradation through its association with the ubiquitin 
ligase complexing protein, βTrCP (161, 163).  The functional domain of Vpu that 
promotes viral egress is the transmembrane (TM) region.  Previous findings have 
suggested that the TM region is required for the ability of Vpu to form an ion channel, 
26 
 
composed of homo-oligomers of Vpu, which is thought to be required for its ability to 
promote viral release (162).    
Vpu is one of several viral encoded proteins known as viroporins that participates 
in several viral functions in addition to promoting virus release (164).  These proteins 
also affect cellular functions such as vesicle transport, glycoprotein trafficking and 
membrane permeability.  In general, viroporins are not absolutely essential for viral 
replication; however, their presence enhances viral replication (164). The oligomerization 
of viroporins within lipid membranes forms hydrophilic pores that enhance the passage of 
ions and small molecules through membranes depending on their concentration gradients 
(164, 165). Exactly how this function of viroporins contributes to viral egress is currently 
unknown.  
 Among the four accessory genes with a cell type dependency phenotype, Vpu is 
thought to be unique to HIV-1 and SIVcpz.  Researchers have recently suggested that the 
evolution of the Vpu gene in an ancestral SIVcpz strain may have led to the current HIV-1 
pandemic as closely related lentiviruses that do not encode a vpu gene are not capable of 
causing severe illness in humans or non-human primates (19, 20, 22, 56). 
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Figure 1.2: The Genomic Organization of HIV-1. The gag and env regions of the viral 
genome encode the structural proteins that form virions at the later stages of the virus 
life-cycle. The pol open reading frame encodes the viral proteins with enzymatic activity. 
Gag, pol and Env are encoded by all retroviruses. The six accessory genes are expressed 
through alternative mRNA splicing events of viral mRNA.    
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Figure 1.3 – The Viral life cycle of HIV-1 (12).  HIV attachs to macrophages and T-
cells by adsorption of glycoproteins on the surface of the virion and receptors on the 
cell’s plasma membrane.  The viral capsid is inserted into the cytoplasm upon 
endocytosis of attached virions and fusion of the viral membrane with the target cells 
plasma membrane.  After uncoating, the reverse transcriptase complex (RTC) converts 
the viral single stranded RNA genome into double stranded DNA while the RTC is being 
transported to the nucleus through microtubule networks.  The viral DNA is then inserted 
into the host genome by the viral integrase enzyme.  Proviral transcription increases once 
the two regulatory viral proteins, Tat and Rev, are expressed.  Full-length unspliced 
mRNAs are then exported to the cytoplasm by Rev, where the viral RNA is translated 
into the structural proteins Gag and Env.  The full-length mRNA also serves as genomic 
RNA and is packaged into assembling virions. In this particular illustration, virion 
assembly and budding is suggested to occur at the plasma membrane specifically.  
However, increasing evidence suggests that virion assembly and budding may occur into 
multivesicular bodies prior to their transport the plasma membrane.  
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 In 2002, APOBEC3G was identified as the first intrinsic restriction factor (58).  In 
the absence of Vif, progeny virions are rendered non-infectious by two distinct functions 
of APOBEC3G.  First, APOBEC3G possesses DNA deamination properties that 
ultimately lead to the degradation of viral cDNA (60, 61).  Secondly, it has also been 
proposed that APOBEC3G may associate with viral RNA, physically impeding reverse 
transcription (59, 160).  In the presence of Vif, APOBEC3G is targeted for degradation 
through ubiquitylation and proteasome degradation, thus enabling infectious virion 
production (62).  
 The Rhesus Macaque (Rh) TRIM5α gene was identified shortly after APOBEC-
3G was discovered (63).  Expression of Rh.TRIM5α in human cell lines blocks viral 
infection at a post-entry step prior to reverse transcription (63).  It has since been 
determined that TRIM5α from various new and old world primates are capable of 
restricting retroviruses in a species specific manner, while human TRIM5α has no effect 
on HIV-1 (64).  It is thought that Rh.TRIM5α inhibits reverse transcription by 
accelerating the rate of decapsidation, perhaps exposing viral RNA to cellular RNases 
(65).  Interestingly, a single amino acid change in the human homologue of TRIM5α 
leads to a similar antiviral phenotype (66).   
 The identification of intrinsic cellular factors has the potential to greatly increase 
the capacity to develop therapeutics against novel targets (67).  Clearly, HIV and SIV 
have evolved accessory genes to target specific cellular factors that block the viral 
replication cycle at different stages (53, 67).  Hence, by inhibiting the function of 
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accessory genes, a potentially powerful new group of antivirals can be developed that 
enable these cellular factors to restrict viral replication.  
2.5 The role of Vpu in Viral Egress 
 As mentioned previously, the second function of Vpu involves its role in 
promoting viral egress (77, 78). The requirement of Vpu for efficient virus particle 
release has been known since the phenotype of a Vpu-deficient HIV-1 clone was first 
characterized nearly twenty years ago (68). Heterokaryon experiments revealed that 
HeLa cells express a cellular factor that is capable of inhibiting virus release in the 
absence of Vpu (69).  
In specific cell lines, Vpu is required for efficient viral release from infected cells.  
Cell lines such as HeLa, Jurkat and CEM and primary cells such as macrophages and 
CD4+ T-lymphocytes all require Vpu for efficient virus release (70, 109).  Hence, these 
cell lines are said to be non-permissive as they require Vpu for efficient viral production.  
In contrast, permissive cell lines such as 293T and COS7 do not require Vpu, as no 
aberrant function is observed in the absence of Vpu expression (109). 
 In 2006, a proteomics study aimed at identifying plasma membrane bound 
cellular factors that were targeted for degradation by the K5 protein of Kaposi Sarcoma 
Herpesvirus and HIV-1 Vpu identified a cellular factor known as Bst-2 (71).  Bst-2 
expression levels were significantly reduced by K5 while Vpu partially reduced its 
expression.  The importance of this finding would not come to realization until two 
groups independently identified Bst-2 as the putative factor responsible for the Vpu-
dependent phenotype (72, 73).   
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Expression of Bst-2 in normally permissive cell lines results in the retention of 
virions at the plasma membrane and subsequent treatment with proteases releases the 
attached virions (72, 73).  Whether or not Bst-2 directly “tethers” virions to the plasma 
membrane is currently under investigation.  However, there are conflicting reports as to 
how Bst-2 prevents viral egress and whether under physiologically relevant conditions, 
the down-regulation of Bst-2 expression by Vpu from the plasma membrane is important 
for viral egress (74-76).  
While Bst-2 is clearly a potent inhibitor of Vpu-deficient viral egress, recent 
reports have suggested that Bst-2 also significantly impairs wild type virus release (79, 
80).  In addition, Bst-2 has been shown to inhibit divergent viruses such as Ebola and 
Herpes Virus suggesting that Bst-2 broadly acts against enveloped viruses in general (81, 
97).  The broad range antiviral activity of Bst-2 is further supported by findings that 
suggest Bst-2 is a component of the interferon response as its expression is IFN-inducible 
(72).   
While several researchers have recently suggested that Bst-2 is the sole cellular 
factor responsible for the Vpu-phenotype observed in various cell types, studies have 
indicated that the majority of T-cell lines and primary CD4+ T-cells do not express Bst-2 
(56, 75).  Since T-cells are a primary target of HIV infection, it is likely that other cellular 
factors exist that contribute to the strong Vpu-dependent phenotype observed in these 
cells.   
 In the following experiments, Bst-2 was used as a standard for comparison with a 
newly identified cellular factor putatively involved in the retention of Vpu-deficient  
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HIV-1 virions, named SNAPIN. As a result of these findings, as well as recently 
published studies, the functional role of Bst-2 in the Vpu-dependent phenotype will be 
discussed in further detail in Chapter VII.    
2.6  SNAPIN: A second cellular restriction factor targeting viral egress 
 Initial experiments aimed at identifying cellular factors that associate with Vpu, 
identified SNAPIN as a Vpu interactor.  Previous research has suggested that SNAPIN 
interacts with late endosomal SNARE proteins and is part of the exocytosis complex that 
is required for the secretion of exosomal vesicles (92, 93). This is particularly interesting 
since it is well known that components of the SNARE-complex are required for HIV-1 
virion egress (94).  Furthermore, previous findings have suggested that HIV virions are 
essentially secreted as exosomes (94-96).   
 Additional insight into the possible role of SNAPIN in viral egress comes from 
previous studies that determined SNAPIN’s involvement in intracellular trafficking of 
cargo proteins to specific endosomal structures including lysosomes (98).  In addition, 
SNAPIN has also been shown to bind to proteins in target SNARE (t-SNARE) 
complexes on donor membranes and promote accelerated fusion with compartments such 
as lysosomes that express cognate vesicle SNAREs (v-SNAREs) (92, 93, 98, 102).  
SNAPIN is also a component of the BLOC-1 complex that is involved in the biogenesis 
of specialized organelles of the endosome-lysosomal systems (99).   
A recent study demonstrated the importance of SNAPIN in the innate immune 
response against Mycobacterium tuberculosis (Mtb).  SNAPIN was shown to interact 
with Irgm-1, an IFN-γ inducible GTPase, which localizes with Mtb containing 
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phagosomes that plays a vital role in the clearance of internalized pathogens (98). It is 
thought that Igrm-1 facilitates the fusion of phagosomes with lysosomes by associating 
with fusogenic SNARE effectors proteins including SNAPIN.  Furthermore, SNAPIN 
was also shown to specifically interact with phosphorylated derivatives of 
phosphatidylinositol (98).  This is particularly intriguing since the lipid envelopes of 
several retroviruses including HIV-1 are enriched with phosphoinositides (166).  
Since viral assembly and the generation of virions are thought to occur via two 
distinct pathways, namely directly at the plasma membrane and through viral assembly 
and retrograde transport via endosomes, a putative role for SNAPIN mediated trafficking 
of Gag is clearly within realm.  By further examining the pathways involved in the 
trafficking of Gag and the assembly of virions at various sites within the cell, the later 
stages of the viral life-cycle can be more accurately defined.  In addition, further analysis 
of the role of SNAPIN in viral egress will undoubtedly lead to a greater understanding of 
the complex network involved in the trafficking of intracellular vesicles and potentially 
how pathogens may alter the targeting of these vesicles to different regions of the cell.  
In the following study, a comprehensive analysis of the putative role of SNAPIN 
in viral egress was examined.  Expression of SNAPIN in normally permissive cell lines 
resulted in a decrease of Vpu-deficient viral titers, while wild type viral titers remained 
relatively unchanged.  In contrast, a reduction of SNAPIN expression in normally Vpu-
dependent cell lines resulted in viral titers approaching wild type levels.  Double 
knockdown of SNAPIN and Bst-2 resulted in titers equal to wild type levels, suggesting 
that SNAPIN and Bst-2 restrict HIV-1 via two independent pathways.  
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 The co-expression of Vpu with SNAPIN resulted in a dose dependent decrease in 
SNAPIN expression. Furthermore, the co-transfection of SNAPIN with wild type proviral 
clones reduced SNAPIN expression, whereas, co-transfection of Vpu-deficient proviral 
clones had no effect.  The degradation of SNAPIN was prevented by the addition of 
either proteasome or lysosomal inhibitors.  In conclusion, this data suggests that Vpu-
mediated degradation of SNAPIN promotes viral egress.  
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Chapter II 
Materials & Methods 
2.1 Clones and Antibodies 
Expression Constructs 
 The SNAPIN and CAMLG inserts were first cloned into pCR2.1-TOPO 
(Invitrogen) after being amplified from EST clones (Open Biosystems).  FLAG-SNAPIN 
and FLAG-CAMLG were constructed using a directional cloning method to insert cDNA 
encoding fragments into pCMV10-3xFLAG (Sigma Aldrich).  The flag BAP construct is 
included as a control when purchasing FLAG-vectors.   
A Bst-2 clone was made from the RT-PCR (Invitrogen) amplification of Bst-2 
from HeLa cells. An untagged pIRES2-Bst2-DsRed clone was made by inserting Bst-2 
cDNA into pIRES2-DsRed (Clontech).   
pcDNA3.1-Vphu.HA was obtained from the AIDS reagent program. This 
construct expresses a codon optimized Vpu allele derived from LAI.  In addition, two 
SIV Vpu clones were also provided by Dr. Evans.  
Proviral Clones 
 pNL-4.3, pADA and HIV-2 were also obtained from the AIDS reagent program.  
Vpu-deficient clones were made using an overlapping PCR method by Cathy Swingler.  
The SIV proviral clones used in this study, SIVCPZ1.69 and 2.69, were a kind gift from 
Dr. David Evans. 
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Antibodies 
FLAG-tagged SNAPIN and FLAG-CAMLG were detected using a rabbit 
polyclonal anti-FLAG antibody purchased from Sigma Aldrich (F7425-.2MG).  HA-
tagged Vpu was detected using a mouse monoclonal anti-HA antibody (sc-7392) while β-
actin was detected with mouse monoclonal antibody sc-69879.  Both antibodies were also 
purchased from Sigma Aldrich.   Anti-p24 antibody was purified from supernatants 
obtained from a hybridoma cell line available through the AIDS reagent program (183-
H12-5C).   
2.2  Primary Cells, Cell lines and Cell Culture  
 The following cell lines were cultured in D-MEM media containing 10% FBS: 
HeLa, TZM-Bl, 293T, HOS, COS7. Additional cell lines were cultured in RPMI media 
containing 10% FBS: Jurkat, CEMx174 and H9.  All cell lines were supplemented with 
L-Glutamine and Pen-Strep. 
 Peripheral blood monocytes were obtained by elutriation. Primary human 
macrophages were obtained culturing purified monocytes in D-MEM containing 10% 
human serum and monocyte colony stimulating factor (MCSF) obtained from RD 
Systems for two days followed by culturing an additional 5 days in the absence of MCSF.  
Peripheral blood lymphocytes (PBLs) and non-differentiated monocytes were collected 
during elutriation. 
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IFNα treatment of macrophages was conducted 7 days after plating as indicated 
above. Spent media was exchange with fresh media containing the specific quantities of 
IFNα indicated in the text 24 hrs prior to infection or 24 hrs post infection unless 
otherwise indicated.  
2.3 Transfections and infections 
Elutriated monocytes were cultured in 24-well plates in DMEM containing 10% 
human serum and MCSF. Seven days later, cells were transfected with 100 nM siRNA 
using lipofectamine 2000 (Invitrogen). Medium was changed four hours after 
transfection.  A second siRNA transfection was repeated the following day.  ON-
TARGETplus SMARTpool siRNAs were used for silencing SNAPIN and Bst2 
(Dharmacon). Silencer-select siRNAs for SNAPIN and Bst2 were used to confirm the 
phenotype (Ambion). Ambion scrambled siRNA was used as control.  Forty-eight hours 
post-first transfection, cells were infected with an equal MOI of wild type or vpu-
deficient HIV-1. Samples were harvested for RNA analysis at the same time. 
Same method was used for siRNA transfection in HeLa and Jurkat cells except that 
oligofectamine (Invitrogen) was used for HeLa cells while HiPerFect reagent (Qiagen) 
was used for Jurkats.  All transfections of expression constructs were conducted using 
TransIT LT as described by the manufacturer (Miruis). 
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2.4 Virus Stocks  
 293T cells were cultured in T-75 flasks prior to transfection.  Cells were co-
transfected with 7 µg of proviral DNA with 700 ng of pMD-VSV-G (plasmid encoding 
VSV enveloped protein under CMV promoter).  Transfection medium was changed four 
hours after transfection with complete media.  Culture supernatants were collected 24 and 
48 hours after transfection.  Supernatants were stored at -80oC in 1 ml aliquots.  
 Viral titers were determined using TZM-Bl cell.  TZM-Bl cells were infected with 
serially diluted viral supernatants.  Twenty-four hours post infection, cells were harvested 
for luciferase assay analysis and titer was determined based on relative luminescence 
units (RLU) of each virus.    
2.5 Yeast Two-hybrid Screening 
 A human macrophage cDNA expression library was constructed using the 
SMART cDNA library construction protocol (Clontech).  The cDNA expression library 
was screened using full-length Vpu as bait according to the Matchmaker GAL4-based 
yeast two-hybrid assay (Clontech).  Cellular proteins that were identified multiple times 
through the screening process are listed in table 3.1. 
2.6 p24 analysis by ELISA 
 Supernatants were collected at the time points indicated and subject to a low 
speed (1500 rpm) centrifugation to remove cellular debris.  Supernatants were then 
diluted in complete media in a 96-well plate and then added to micro-titer plates coated 
with α-p24 antibody.  Depending on cell line used, a 1:10 or 1:20 dilution of supernatants 
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generally resulted in readings within the range of the assay.  Viral titers were determined 
according to the HIV-1 p24 ELISA kit from Perkin Elmer (NEK050B).       
2.7 p24 analysis by Western Blotting 
 Supernatants were harvested as described in the previous section.  After filtration, 
500 µl of supernatants were passed through a 20% sucrose cushion gradient by spinning 
samples for 2 hours at 14,000 rpm. Viral pellets were then lysed in 20 µl of SDS-PAGE 
loading buffer and heated to 95oC for 5 minutes.  Samples were then loaded on a 14% 
SDS-PAGE gel and transferred to a nitrocellulose membrane for blotting with a 
monoclonal αp24 antibody. 
2.8 Immunoprecipitation 
 SNAPIN and Vpu interaction was further verified using two immunoprecipitation 
approaches.  In the first approach, an equal amount of FLAG-SNAPIN and Vphu.HA 
plasmid was transfected into 293T cells.  Twenty four hours later, the proteasome 
inhibitor, MG132, was added to transfected cells.  After an additional twenty four hours, 
cells were harvested and pelleted by low speed centrifugation (1500 rpm).  Cells were 
then lysed in 500 µl of ice-cold lysis buffer containing 50mM NaCl, 20 mM Tris-HCl, 
0.1% NP40 (pH 7.4).  Cell lysates were then cleared of cellular debris and genomic DNA 
by high speed centrifugation (10,000 rpm for 15 minutes).  Ten percent of cleared lysates 
was kept for Western Blot analysis of lysates while the remainder was subjected to 
immuno-precipitation using anti-FLAG coated resin (Sigma Aldrich, catalog#A2220).  
Lysates were incubated with resin for 3 hours at 4oC in a rotation. Resin was then 
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collected at the bottom of the tube by low speed centrifugation and the post-IP 
supernatants were kept for further analysis of the efficiency of the immuno-precipitation 
protocol. Samples were then washed five times in 1 ml lysis buffer (15 minutes each 
wash) prior to the addition of 50 µl SDS-PAGE loading buffer.  Samples were then 
heated at 95oC for 5 minutes and placed on ice prior to being separated on a 14% SDS-
PAGE gel.  In the second immuno-precipitation, bacterially expressed GST-SNAPIN was 
incubated with lysates from 293Ts expressing Vphu.HA. GST precipitation was 
conducted according to manufacturer’s protocol (Pierce, Catalog# 21516). 
2.9  Viral Inhibition Assays 
 Viral inhibition assays were conducted in two Vpu-independent cell lines, 293Ts 
and COS7.  Cells were seeded in 12-well plates and after overnight culture, were co-
transfected with proviral DNA and increasing amounts of FLAG-SNAPIN.  Empty 
pcDNA3.1 was added accordingly to obtain approximately equal promoter units in each 
transfection.  Supernatants were collected at 24 hour intervals for four days post-
transfection. Cellular debris was removed by low speed centrifugation prior to freezing 
samples at -20oC.  Viral titers were determined by ELISA or Western Blotting as 
previously described.   
2.10 Degradation experiments 
 293Ts were seeded in 12-well plates and cultured overnight prior to transfection. 
A constant amount of FLAG-SNAPIN (200 ng) was co-transfected increasing amounts of 
Vphu.HA or untagged Vpucpz plasmid (as indicated in figures).  Empty pcDNA3.1 was 
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added accordingly to maintain equal promoter units in each transfection.  Cells were 
harvested forty-eight hours post transfection and lysed in 150 µl of RIPA buffer.  3.5 to 
5% of lysates were separated on 14% SDS-PAGE gels and transferred to nylon 
membrane using standard Western Blotting techniques.  Blots were incubated in 
sequential order with anti-FLAG, anti-HA and anti-β-actin antibodies.   
 For degradation experiments using proviral DNA, an equal amount of FLAG-
SNAPIN was co-transfected with increasing amounts of proviral DNA as indicated in the 
text. Cells were collected 72 hours after co-transfection and lysed in RIPA buffer as 
previously described.  Intracellular Gag was detected using a mouse monoclonal anti-p24 
antibody.  
2.11 Proteasome and Lysosome inhibition Assays 
 293Ts were seeded in a 12-well plate 24 hours prior to transfection.  Four master 
mixes were prepared with each containing equal amounts of FLAG-SNAPIN (200 ng per 
well).  The equivalent of 100 ng, 200 ng or 400 ng per well was added to each of three 
master mixes.  Empty pcDNA-3.1 vector was then added to normalize all transfections.  
Twenty-four hours after transfection, 10 µM of the proteasome inhibitor MG132 was 
added to one row of transfected cells. 20 µM chloroquine or 10 µM E-64, both of which 
are lysosomal inhibitors, was added to two additional transfected rows while media 
containing DMSO was added to the remaining row as a negative control. Twelve to 
fourteen hours after the addition of the inhibitors, cells were harvested, lysed and blotted 
as described in section 2.10.  Additional blotting was conducted using anti-p21 antibody 
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to demonstrate the efficiency of proteasome inhibition while anti-cyclin T1 antibody was 
used as a loading control.  
2.12  Subtilisin treatment 
Two protease digestion experiments were conducted to determine whether 
SNAPIN and Bst-2 tethered virions at the plasma membrane as previously described.  In 
the first protease digestion experiment, Jurkats were pre-transfected with siRNAs 
targeting SNAPIN, Bst2 or a control scrambled siRNA.  After 48 hrs, siRNA transfected 
cells were infected with VSV-G pseudotyped wild type or Vpu deficient virus.  After an 
additional 48 hrs, supernatants were collected after a brief centrifugation at 1500 rpm to 
pellet cells.  The virus in the initial supernatant represents the constitutive amount of 
virus released from infected cells and was labeled C. The cell pellets were then re-
suspended in 500 µl of PBS, divided in two and centrifuged again to collect washed cells.   
 Half the pelleted cells were re-suspended in protease buffer alone while the 
second half was re-suspended in protease buffer containing 1 mg/ml subtilisin.  Cells 
were then incubated at 37oC for 30 minutes before protease activity was inhibited by the 
addition of 500 µl complete media.  Cells were pellet again as previously indicated and 
the supernatants were collected and marked as either buffer treated (B) or subtilisin 
treated (S).  Cell pellets were lysed in 150 µl of RIPA buffer. 
 The remaining supernatants were then processed through a 20% sucrose cushion 
gradient to pellet virions as previously described.   p24 levels in supernatants and 
p24/p55 expression in cell lysates, were analyzed by Western blotting using an αp24 
monoclonal antibody. 
43 
 
2.13  Real-time PCR analysis 
 For silencing studies, the cells were harvested for RNA analysis 48 hours post 
siRNA transfection.  RNA was purified using Qiagen RNeasy Kit.  cDNA was prepared 
from purified RNA using Applied Biosystems Reverse Transcription Kit.  Copy number 
of SNAPIN and Bst-2 mRNA was measured using quantitative PCR on an AB7500 fast 
machine.  The mRNA levels for each gene were normalized to GAPDH or β-actin.   
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Chapter III 
Identification of SNAPIN & Analysis of the Vpu-phenotype 
3.0  Chapter Summary 
In this chapter, nine cellular factors that putatively interact with Vpu were 
identified using a yeast two-hybrid screen approach.  Prior to confirming their 
interactions with Vpu, shRNA cell lines were made to determine whether decreased 
expression of each gene on its own could alter the Vpu-phenotype normally observed in 
HeLa cells.  Using this method, SNAPIN was identified as one of three cellular factors 
with a potential role in the Vpu-phenotype.  Immunoprecipitation experiments verified 
that the interaction between Vpu and SNAPIN was specific. 
Attempts to examine if the relative expression of SNAPIN in various cell types 
corresponded with the Vpu-phenotype were inconclusive due to a lack of a suitable 
antibody.  However, similarly to Bst-2 mRNA expression levels, SNAPIN mRNA was 
found in both Vpu-dependent and independent cell lines.  Previous examination of Bst-2 
protein levels in the same cell lines, however, suggested that mRNA expression levels did 
not necessarily correlate with protein levels (75). 
The known cellular localization of SNAPIN, Bst-2 and the two viral proteins, Vpu 
and Gag, are summarized in order to determine potential sites of cellular interaction.  
However, further examination of the cellular distribution of these proteins was not 
conducted in these studies.  The effects of IFN-treatment of macrophages on viral 
replication were also examined and compared with recent literature suggesting IFN does 
not inhibit wild type HIV-1. 
45 
 
3.1 Yeast two-hyrbid and shRNA cell line results 
 In an attempt to identify cellular factors that were potentially regulated by Vpu, a 
yeast two-hybrid cDNA library derived from human macrophage RNA was screened 
using full-length Vpu as bait.  Several screens were conducted, resulting in the 
identification of 9 cellular factors with multiple hits (Table 3.1).  Several intriguing 
cellular factors with functions ranging from protein turnover, to ubiquitin ligase adapters 
and cellular trafficking were identified.   
 Once putative Vpu-interactors had been identified, two shRNA cell lines were 
made for each gene in HeLa cells.  HeLa cells were chosen since they are relatively 
hardy, adherent and most importantly, have a well characterized Vpu-dependent 
phenotype.  It was expected that if any of the factors listed in table 3.1 were the cause of 
the Vpu-phenotype in HeLa cells, the down-regulation of the specific gene should 
alleviate the Vpu-phenotype.  
 The shRNA cell lines were then transfected with equal amounts of wild type or 
Vpu-deficient HIV-1 proviral clones.  Supernatants were collected 48 and 96 hrs post-
transfection and the total amount of p24 in each sample was determined by p24 ELISA.  
Viral titers from each shRNA cell line were then compared with virus released from a 
HeLa cell line expressing scrambled shRNA.  In some cases, the amount of virus released 
was adversely affected by the expression of the gene specific shRNA while in other 
shRNA cell lines, no increase in Vpu-deficient viral titers were observed (Appendix I). 
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Three putative candidates were identified that increased the ratio of Vpu-deficient 
to wild type virus released (figure 3.1).    Both shRNA cell lines targeting attractin 
(ATRN) resulted in an increase of Vpu-deficient virus to approximately 72-75% of wild 
type.  When compared to the amount of Vpu-deficient virus released from the shRNA 
control cell line, an increase of 40 to 45% is observed.  While the increase was quite 
significant at 48 hrs, the effects of decreased attractin expression were not as evident at 
96 hrs.   
 Decreased CAMLG expression resulted in an increase of 30 to 35% over the 
shRNA control cell line at 48 hrs (figure 3.1; sh.CAMLG.1 and 2).  When compared to 
wild type titers, targeted knockdown of CAMLG results in an increase of Vpu-deficient 
virus to approximately 55 to 60% wild type levels.  However, similar to what was 
previously observed in the attractin shRNA cell lines, the percentage Vpu-deficient virus 
released only increased by 25 to 40% at 96 hrs over scrambled shRNA cell lines.  In 
general, Vpu-deficient virus released from shRNA control cell lines results in viral titers 
roughly between 25 to 30% of wild type levels.   
 Decreased expression of only one cellular factor, SNAPIN, resulted in increased 
Vpu-deficient viral titers at both 48 and 96 hr time points (figure 3.1; shSNAPIN.1).  
Vpu-deficient viral titers between 65 to 70% of wild type levels were detected at both 
time points.  In comparison to shRNA control cells, Vpu-deficient viral titers increased 
between 2.8 to 3.6-fold  in HeLa cells expressing shRNA targeting SNAPIN.   
 Of interest were the results from the second shRNA cell line targeting SNAPIN 
(shSNAPIN.2).  As indicated in figure 3.1b, SNAPIN mRNA levels remained at over 
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40% in this cell line compared to the less than 20% expression levels detected in 
shSNAPIN.1.  This suggests that the level of reduction of SNAPIN directly influences 
the extent of Vpu-deficient virus release.  Only a 2.2-fold increase was observed in the 
second SNAPIN shRNA cell line as opposed to a 3.6-fold increase in cell lines 
expressing shSNAPIN.1 at 96 hrs.     
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Table 3.1: Putative Vpu-interactors identified by yeast two-hybrid experiments. 
Full-length Vpu was used as BAIT in a yeast two-hybrid screen to identify potential Vpu-
interactors.  A cDNA library was constructed from human macrophage RNA according 
to the SMART cDNA expression library protocol (Clontech).  Cellular factors listed in 
table 3.1 represent proteins identified through multiple hits (minimum of two).  Brief 
descriptions of the known functions are presented. 
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Figure 3.1: HeLa shRNA cell lines that alleviate the Vpu-dependent phenotype. 
Three shRNA cell lines were identified with a putative Vpu-dependent phenotype.  Two 
HeLa shRNA cell lines targeting each gene were screened for a decrease in Vpu-
dependent phenotype by comparing Vpu-deficient viral production as a percentage of 
wild type titers (panel A).  p24 ELISA analysis was conducted 48 and 96 hrs post 
transfection of proviral DNA.  The percentage decrease of shRNA targets was 
determined by Real-time PCR and compared with mRNA levels of the sh.control cell 
line. Average of triplicate samples shown. 
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3.2 Immunoprecipitations 
 To verify the yeast two-hybrid results that suggested that Vpu interacted with 
SNAPIN, immunoprecipitation experiments were conducted using both mammalian and 
bacterial expression systems.  As a control, CAMLG was included in these experiments 
as previous reports demonstrated that CAMLG interacts with Vpu (100).  Interestingly, 
initial attempts to immunoprecipitate SNAPIN with Vpu were unsuccessful as the co-
expression of Vpu with SNAPIN led to a significant decrease in SNAPIN expression.  
Later experiments would demonstrate that Vpu specifically targets SNAPIN for 
degradation.  
 Therefore, to prevent the degradation of SNAPIN by Vpu, the proteasome 
inhibitor, MG132, was added to the media 24 hrs after transfection.  As demonstrated in 
figure 3.2a, FLAG-SNAPIN, FLAG-CAMLG and Vphu.HA were readily detectable in 
lysates (top two panels).  Immuno-precipitation using anti-FLAG antibody coated beads 
successfully precipitated the majority of FLAG-SNAPIN and FLAG-CAMLG from 
lysates as minimal amounts of either were detected in post-IP Western Blots of lysates.   
 Western blotting analysis of IP samples with anti-HA antibody clearly revealed 
that Vphu.HA was pelleted in samples expressing FLAG-SNAPIN (figure 3.2a; bottom 
two panels).  Importantly, Vphu.HA was not detected in IPs from 293T lysates 
expressing only Vphu.HA suggesting that the interaction with SNAPIN was specific.  
Furthermore, Vphu.HA was also detected in FLAG-CAMLG immunoprecipitations as 
previously reported (100). 
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The amount of Vphu.HA observed in cells co-transfected with FLAG-CAMLG, 
however, was less than the amount detected in lysates from 293Ts co-transfected with 
FLAG-SNAPIN and pcDNA3.1-Vphu.HA.  For this reason, the amount of Vphu.HA co-
immunoprecipitated using anti-FLAG antibody coated beads from 293Ts co-expressing 
CAMLG was reduced.  Nonetheless, immunoprecipitation of FLAG-CAMLG further 
verified the interaction of CAMLG with Vphu.HA, which served as an excellent control 
for these experiments. 
 Immunoprecipitations using bacterially expressed GST-SNAPIN also 
demonstrated that SNAPIN and Vpu interacted.  A significant amount of Vphu.HA was 
detected in the IP pellet from lysates mixed with GST-SNAPIN (figure 3.2b). However, a 
faint band was also observed when Vphu.HA expressing lysates were 
immunoprecipitated with GST-alone.  This band most likely represents residual 
Vphu.HA that was not cleared during buffer washes of immunoprecipitated complexes.  
Taken with results from figure 3.2a, in addition to yeast two-hybrid results, SNAPIN 
likely interacts directly with Vpu.   
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Figure 3.2: Immunoprecipitation of Vpu with SNAPIN. FLAG-SNAPIN was co-
expressed with Vphu.HA in 293Ts (panel A).  Lane 1: FLAG-SNAPIN alone; Lane 2: 
Vphu.HA alone; Lane 3: FLAG-CAMLG; Lane 4: FLAG-SNAPIN + Vphu.HA; Lane 5: 
FLAG-CAMLG + Vphu.HA; Lane 6: Agarose beads alone.  Top two panels are Western 
Blots of lysates while bottom blots are of immunoprecipitated samples.  Panel B: 
Bacterially expressed GST-SNAPIN was mixed with lysates from 293Ts transfected with 
pcDNA3.1-Vphu.HA.  Top panel: Immunoprecipitation.  Bottom panel: Lysates.  Lane 1: 
GST-SNAPIN IP with Vphu.HA lysates; Lane 2: GST-SNAPIN with Vpu; Lane 3: GST-
SNAPIN with empty pcDNA3.1-vector; Lane 4: GST with Vphu.HA.  Note: Ladder 
detected by secondary antibody in Panel A, anti-FLAG lysates blot. 
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3.3 Expression analysis 
 Since the Vpu-dependent phenotype varies from cell to cell, mRNA levels of both 
SNAPIN and Bst-2 were determined in a number of cell lines and primary cells. As 
determined by Real-time PCR, SNAPIN mRNA was detected in all cell lines tested.  
SNAPIN mRNA levels were the highest in macrophages, however, SNAPIN mRNA 
levels were also relatively high in 293Ts (figure 3.3, Panel A).  This was unexpected as 
293Ts do not have a Vpu-dependent phenotype.   
 While SNAPIN mRNA was detected, previous reports determined that SNAPIN 
was not detectable at the protein level in 293Ts (figure 3.3, Panel C) (101).  The exact 
reason for this discrepancy is not clear, however, SNAPIN is known to have at least four 
isoforms.  Whether different cell types express different isoforms remains to be 
determined, however, there is still the possibility of post-transcriptional control of 
SNAPIN expression.   
 The levels of SNAPIN mRNA expression remained relatively the same in HeLa, 
Jurkats, PBLs and H9 cells.  As demonstrated in figure 3.3D, COS7 cells do not express 
detectable SNAPIN at the protein level, which was expected as COS7 cells do not 
possess a Vpu-dependent phenotype (102). Surprisingly, however, COS7 cells do express 
Bst-2 and yet these cells do not have a Vpu-dependent phenotype (Figure 3.4, Panel C) 
(103).  
Unfortunately, attempts to generate a rabbit polyclonal antibody against SNAPIN 
failed to detect even transiently expressed FLAG-SNAPIN (figure 3.3, Panel E).  Only 
one band of approximately 12kDa was detected in a molecular weight range close to the 
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molecular weight of SNAPIN (17kDa).  However, the same band was apparent in pre-
immune serum as well as lysates from cells transfected with siRNAs targeting SNAPIN.   
While mRNA analysis of SNAPIN did not provide definite information about the 
normal endogenous levels of SNAPIN, the analysis of Bst-2 mRNA expression is equally 
puzzling when compared to the protein levels detected by previous groups (figures 3.3b 
and 3.4c) (75).  According to mRNA expression levels, macrophages should express as 
much if not more Bst-2 than HeLa cells.  However, as figure 3.4c demonstrates, 
macrophages express at least 10-fold less Bst-2 protein.   
 Furthermore, Bst-2 expression levels in PBMCs, Jurkats, and A3.01 cells has 
been shown to be nearly undetectable and yet, the cell types listed in Group B have the 
highest known differences in Vpu-deficient virus to wild type production (figure 3.4; 
Panel C).  Furthermore, as mentioned previously, COS7 cells express high levels of 
African Green Monkey (AGM) Bst-2 (103).  This is significant as AGM Bst-2 has been 
shown to potently inhibit HIV-1 when expressed in trans (104).  Unfortunately, no 
explanation has been given as to why these cells do not restrict Vpu-deficient virus.  
 Similarly, the mRNA levels of both PBLs and monocytes would suggest the Bst-2 
protein expression would be readily detectable in lysates.  However, Bst-2 is apparently 
absent from PBMCs lysates (figure 3.4c, group B) (75).  Furthermore, and perhaps most 
surprisingly, Bst-2 mRNA levels in Jurkat cells are nearly undetectable.   This finding 
further illustrates that Bst-2 is not expressed in all cell lines known to have a Vpu-
dependent phenotype.   
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Figure 3.3: mRNA expression analysis of SNAPIN & Bst-2 in various cells types. 
Real-time PCR analysis was used to determine the relative levels of SNAPIN and Bst-2 
mRNA expression in various cell lines and primary cells (Panel A and B). Previously 
published reports indicate that SNAPIN is not expressed in 293Ts or COS7 cells as 
determined by Western Blotting (Panels C and D).  Western blot analysis of 293T lysates 
expressing FLAG-SNAPIN using in-house rabbit polyclonal serum (Panel E, top two 
panels) or anti-FLAG antibody (bottom panel).  Only a 12 kDa background band was 
detected in lysates, which was also observed in pre-immune serum.  Panel C & D, 
reference 101 and 102, respectively. Lane 1 in Panel C and lane 2 in panel D are 
transfected with SNAPIN expression plasmids.  
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3.4 Vpu-dependent phenotype in cell lines & primary cells 
 As previously mentioned, the requirement for Vpu is cell type specific.  
Examination of the data obtained over the course of these experiments as well as 
previously published findings, suggests that there are three groups of Vpu-dependent cell 
types (figure 3.4). Group A, which includes HeLa and CEMx174 cells, possesses a 
moderate Vpu-dependency phenotype.  In general, the difference in the amount of p24 
detected in cells infected with wild type virus compared to Vpu-deficient virus is only 2.5 
to 3.5-fold  higher (figure 3.4, panel B). 
 The cell types in group B, however, represent cells that show a great deal of 
dependency on Vpu-expression.  The ratio of Vpu-deficient virus in these cells is 
typically between 5 to 8-fold less than wild type levels (figure 3.4, panel B).  The cells 
listed in Group A are not natural target cells for HIV infection, whereas the cell types 
listed in group B represent cell types that have been well characterized targets of HIV 
(e.g. macrophages and T-cells).   
 As for group C, the Vpu-independent cell types, Vpu-expression has absolutely 
no effect on viral production.  However, when examining Bst-2 protein expression levels 
in group C, high Bst-2 expression levels are clearly visible in COS7 cells (figure 3.4, 
Panel C) (103).  As mentioned in the previous section, AGM Bst-2 has been shown to 
significantly impair HIV-1 production (104).  Conversely, the cell types in group B 
express little to no Bst-2, and yet they represent the group of cells with the highest Vpu-
dependency (75, 109).    
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 It should be noted that while CEMx174 cells are a fusion of a T-cell and B-cell 
line, Bst-2 is known to be highly expressed on B-cells specifically (105).  Nonetheless, 
the cell lines in group A express the highest amounts of endogenous Bst-2, and yet the 
Vpu-phenotype is only moderate in these cells.  Clearly, there is no correlation between 
Bst-2 expression levels and the Vpu-phenotype.   
 It has been proposed that the internal aggregates that are normally observed when 
Gag-GFP is transfected into HeLa cells are a marker for cells with a Vpu-phenotype 
(106).  However, as demonstrated in figure 3.4D, Gag-GFP aggregates are clearly visible 
when Gag-GFP is transfected into COS7 cells.  These results have been previously 
observed, and in addition, internal aggregates have also been observed in 293Ts (106, 
107).  Since 293Ts do not express Bst-2, the internal aggregates observed by fluorescent 
microscopy of Gag-GFP transfected cells cannot be attributed to Bst-2 expression and are 
not an indicator of the Vpu-dependent phenotype. 
 While further fluorescent microscopy studies were not conducted to determine 
whether SNAPIN and Gag-GFP co-localize, table 3.2 illustrates the known cellular 
distribution of SNAPIN, Bst-2 and viral proteins.  While it appears that SNAPIN is 
distributed on nearly all cellular membrane organelles, including the plasma membrane, 
experiments conducted in Chapter VI suggest that SNAPIN and Vpu interact in 
lysosomes.  Interestingly, Gag and SNAPIN may interact at one of two cellular 
localizations; the plasma membrane or late endosomes. 
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Figure 3.4: Vpu-phenotype in select primary cells and cell lines. The relative 
differences in viral titer between wild type and Vpu-deficient virus were determined in 
the indicated cell lines (Panel A).  The percentage difference between Vpu-deficient virus 
and wild type virus is indicated in panel B.  Panel C is a modified image of Western Blot 
analysis of Bst-2 expression by Strebel et al and Howard (COS7 analysis) and meant for 
comparison between the extents of the Vpu-phenotypes observed in various cells with the 
amount of Bst-2 expressed in the corresponding cells.    Fluorescent microscopy of Gag-
GFP expressing HeLa and COS7 cells reveals the formation of internal aggregates (Panel 
D). (Panel C, modified ref. 75 and 103). 
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Table 3.2: Cellular distribution of SNAPIN, Bst-2, Vpu and Gag. Table lists the 
known cellular localizations of SNAPIN, Bst-2, Vpu and Gag.  Cellular localization was 
determined by fluorescent microscopy using organelle specific markers and/or 
biochemical experiments.   
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3.5 IFNα treatment & viral replication 
 Recent reports have suggested that Vpu evolved specifically to overcome Bst-2’s 
antiviral activity during an interferon response (56, 97).  Surprisingly, researchers have 
demonstrated that wild type HIV can escape the effects of IFNα by counteracting Bst-2 
(103).  As figure 3.5 demonstrates, IFNα potently inhibits wild type virus in 
macrophages.  Treatment of macrophages prior to infection significantly blocked viral 2-
LTR production (figure 3.5, Panel A).  Even at the lowest concentration of 0.5 U/ml, 
IFNα significantly blocked viral infection early in the virus life-cycle. 
 The addition of IFNα 24 hrs after infection also had a significant effect on wild 
type virus (figure 3.5, Panel B).  Even after proviral integration into the host genome was 
allowed to occur, IFNα decreased wild type virus production by 7 to 8-fold.  The amount 
of virus in supernatants began to increase at 96 hrs, however, this was most likely due to 
the uptake of IFNα by macrophages over the course of the experiment.  These findings 
clearly demonstrate that wild type virus is actually highly attenuated by IFN-treatment. 
 Therefore, it is unlikely that Vpu’s ability to counteract Bst-2 would be capable of 
counteracting the effects of IFN-treatment.  These experiments, in addition to recently 
published studies, indicate that IFN induces several layers of restriction that block viral 
replication at different stages of the viral life-cycle (108).  In a cellular context, 
transcription and translation of cellular genes is significantly impaired in order to limit 
viral replication. 
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Figure 3.5: Effects of IFN-treatment on wild-type virus in macrophages. 
Macrophages were treated with log-dilutions of IFNα prior to infection with NL4.3.  
After 24 hrs, cells were harvested and lysed in RNA lysis buffer.  2-LTR levels were 
determined using Real-time PCR analysis as described in the material & methods section 
(Panel A).  In panel B, macrophages were pre-infected with wild type or vpu-deficient 
viruses.  24 hrs post-infection, spent media was replaced with fresh media containing 30 
U/ml or 100 U/ml of IFNα. Supernatants were harvested 48 h and 96 h after the addition 
of IFNα.  Viral titers were determined using TZM-Bl cells by measuring luciferase 
activity. mRNA was analysed to determine the relative effects of IFNα treatment on 
SNAPIN and Bst-2 expression levels (Panel C).   
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Chapter IV 
Expression of SNAPIN in permissive cell lines restricts viral 
release in a Vpu-dependent manner 
 
4.0  Chapter Summary 
 
Several groups have shown evidence that Bst-2 seems to be the cellular factor 
responsible for the Vpu-phenotype. Indeed the expression of a relatively small amount 
(50 to 200 ng) of Bst-2 expression plasmid in a normally permissive cell line, such as 
293Ts, reduces Vpu-deficient viral titers by nearly two-logs (72).  However, these studies 
used TZMB-Bl cell lines that are derived from HeLa cells to measure infectious units.   
Since it has been well established that HeLa cells are Vpu-dependent, using 
TZMB-Bl cells to measure infectious units results in the amplification of the actual 
variations between wild type and Vpu-deficient virus. Therefore, in these experiments 
viral production was determined based on p24 levels and measured quantitatively by 
ELISA or qualitatively by Western Blotting.  
The results obtained in this chapter indicate that transfection of SNAPIN into 
normally permissive cell lines reduces Vpu-deficient viral titers.  This association was 
further correlated using a dose-dependent assay that resulted in a greater reduction in 
Vpu-deficient viral titers as SNAPIN expression levels increased.  In addition, these 
experiments also demonstrated that SNAPIN expression is reduced in the presence of 
proviral clones expressing Vpu specifically.  
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4.1 Determining the Range of SNAPIN activity 
The initial experimental results obtained in figure 4.1 aimed at identifying a 
minimum and maximum range with which to conduct further experiments.  Panel A and 
panel B represent wild type and vpu-deficient viral production when 800 ng of proviral 
DNA was co-transfected with 150 ng of  FLAG-tagged SNAPIN, FLAG-tagged BAP, 
FLAG-tagged CAMLG or untagged Bst-2 per well of a 6-well plate.  COS7 cells were 
used for these experiments due to their strong adherence, robust capacity for viral 
production and absence of a Vpu-dependent phenotype.  
As indicated in panel A, FLAG-tagged SNAPIN had a minimal effect on wild-
type virus when compared to COS7 cells transfected with the control vector expressing 
FLAG-tagged BAP.  The effect of FLAG-SNAPIN on Vpu-deficient virus was somewhat 
modest as only a 50% reduction of viral titers was observed.  These results suggested that 
this ratio of SNAPIN to proviral DNA was at or near the bottom end of a detectable 
SNAPIN phenotype.   
In comparison, the expression of FLAG-tagged CAMLG seemed to reduce both 
wild type and Vpu-deficient viruses equally (figure 4.1).  The only significant variation 
between COS7 cells co-transfected with CAMLG and Vpu-deficient virus was observed 
at the 48 h time point, where viral titers were reduced by approximately 35% compared to 
the BAP control.  At later time points, cells expressing CAMLG produced Vpu-deficient 
virions at a similar rate to control cells.  These results were not entirely surprising as the 
initial experiments that identified CAMLG as a putative candidate for the Vpu-phenotype 
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used a far greater quantity of CAMLG expression constructs (100).  However, the 
absence of a Vpu-specific phenotype was unexpected.  
The co-expression of Bst-2 with proviral DNA had a significant effect not only on 
Vpu-deficient virus, but also on wild type virus (figure 4.1, Panel A).  Wild-type virus 
production was reduced to 30% of BAP control while Vpu-deficient virus titers were 
reduced to approximately 10% of control wells.  These results demonstrate two attributes 
of Bst-2’s antiviral activity; first, Bst-2 is an extremely potent antiviral cellular factor; 
and second, Bst-2’s antiviral activity is also capable of restricting wild-type virus.  These 
results have previously been reported and have led researchers to use minimal amounts of 
Bst-2 to amplify the differences between wild-type and Vpu-deficient virus (72, 73).   
While the previous experiments were used to determine the low range of DNA 
required to obtain a Vpu-dependent phenotype, the results in panel C were used to 
determine a maximal range for co-transfection that would minimally affect wild-type 
levels.  These experiments were conducted in the same manner as in the minimal 
expression experiments, however, 1 µg of restriction factor plasmids were used while the 
amount of proviral DNA remained constant at 800 ng.  
As the results indicate, the co-expression of BAP had no effect on either wild-type 
or Vpu-deficient virus production.  In fact, viral titers remained at similar levels as those 
observed when cells were transfected with minimal amounts of BAP DNA.  These results 
suggest that the use of FLAG-tagged BAP was a suitable negative control for these 
experiments.  
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In these experiments, both SNAPIN and CAMLG appeared to have a nearly 
identical profile, as viral titers for both wild type and Vpu-deficient viruses followed 
similar kinetics. At 96 hrs post co-transfection, a maximal decline of 50% was observed 
in wild type levels in cells transfected with 1 µg SNAPIN or CAMLG.  Similarly, at 96 
hrs a maximal decrease in Vpu-deficient virus was also observed with titers reaching 
levels of only 15% to 20% of BAP control samples. These results indicated that both 
SNAPIN and CAMLG were capable of reducing viral titers of both wild type and vpu-
deficient virus, with an average of 30% to 35% further reduction in Vpu-deficient viral 
titers being observed.  
The co-transfection of 1 µg of Bst-2 resulted in a significant drop of both wild 
type and Vpu-deficient virus.  Viral titers reached near or at the bottom of the detection 
limit of the assay.  A decrease of greater than two-logs was observed, however, no 
discernable differences were observed between wild type and vpu deficient virus 
production.  This is likely due to a saturation of Vpu’s ability to block the antiviral effects 
of Bst-2.  Since a similar effect was previously observed in experiments using 150 ng of 
Bst-2 expression plasmid, the co-transfection of an even greater amount of Bst-2 was 
expected to further reduce viral titers of both wild type and mutant viruses. 
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Figure 4.1: Determination of range of SNAPIN antiviral activity. The effects of a 
minimal amount (150 ng) of restriction factor plasmids on wild type and Vpu-deficient 
viral titers were determined by p24 ELISA (Panel A and B).  Increased amounts (1 µg) of 
restriction factor plasmids were used to identify a maximal range for future co-
transfection experiments (Panel C).  Experiments performed in 6-well plate format using 
800 ng proviral clones in co-transfections with restriction factor plasmids.  Results are an 
average of triplicate wells. Panels A and B: closed circles = BAP; open circles = CAML; 
closed triangle = SNAPIN; open triangle = Bst-2.   
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4.2  SNAPIN expression reduces Vpu-deficient virus release in a dose-dependent 
manner 
 
While the results from the aforementioned experiments revealed promising results 
as to a possible role of SNAPIN in the Vpu-dependent phenotype, the finding that 
SNAPIN expression only resulted in a reduction in Vpu-deficient virus titers of 
approximately 35% of the effect of SNAPIN on wild-type virus, suggested that further 
modifications of the experimental protocol used in the initial experiments were required.   
In an attempt to standardize further expression experiments, the following 
changes were made in order to reduce variations in sample transfection and analysis of 
viral titers; first, all wells were transfected with an equal amount of total promoter units 
using empty pcDNA3.1 vector; second, viral titer in lysates were determine either by 
ELISA or Western Blotting to ensure that decreased viral titers were not due to variations 
in transfection efficiency.  In addition, 12-well plates were used as a substitute for 6-well 
plates, in accordance with previously published methods used for examining the effects 
of Bst-2 (72).  
Using the new standardized protocol, the effects of the each restriction factor 
plasmid became more apparent at 72 and 96 hrs post co-transfection.  As previously 
determined, the co-transfection of BAP had minimal effects on wild type or Vpu-
deficient virus as no statistical differences were observed. Overall, the amount of Vpu-
deficient virus was similar to the levels released from wild type virus co-transfected with 
BAP.  
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No significant differences were observed when Vpu-deficient virus was co-
transfected with 100 ng of FLAG-tagged CAMLG at 72 h or 96 h post-transfection 
(figure 4.2).  However, when 333 ng or 1 µg of CAMLG were co-transfected, a 
statistically significant decrease of 24% and 40% was observed at 72 and 96 hrs (P 
<0.05). When examining the effect of CAMLG on wild type virus production, no 
significant differences were observed.  Therefore, while CAMLG does appear to induce a 
Vpu-dependent phenotype when expressed in an otherwise Vpu-independent cell line, the 
percentage decrease in viral titer does not represent levels normally associated with cell 
lines and primary cells that possess a Vpu-dependent phenotype.  
Upon examining the effects of SNAPIN in COS7 cells, a statistically significant 
decrease in Vpu-deficient virus is observed with all 3 concentrations used in these 
experiments at 96 hrs (figure 4.2).   A reduction in viral titers to 25%, 13% and 10% of 
BAP transfected control titers was observed when COS7 cells were co-transfected with 
100 ng, 333 ng and 1 µg of FLAG-SNAPIN plasmid, respectively. At 72 hrs, the two 
higher concentrations of SNAPIN resulted in a 55% and 87% reduction in viral titers 
compared to control viral titers.  Importantly, no significant decrease was observed when 
the wild-type proviral clone was co-transfected with increasing amounts of SNAPIN, 
although a decreasing trend is clearly evident at higher concentrations (P = 0.0796).  
p24 ELISA analysis of supernatants revealed a reduction of approximately 1-log 
when COS7 cells were transfected with 100 ng of Bst-2 expression plasmid (figure 4.1). 
This is in accordance with values obtained by Van Damme et al. (73).  Similarly, the 
transfection of 100 ng of SNAPIN expression vector in 293Ts, resulted in an 
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approximately 8-fold reduction in Vpu-deficient viral production.  Transfection of higher 
concentrations of both SNAPIN and Bst-2 also reduced the amount of wild-type virus 
released from cells.  This suggests that the anti-restriction activity of Vpu can be 
saturated, which in the case of Bst-2, has previously been shown (73).   
These experiments clearly demonstrated the potent antiviral activity of Bst-2 as 
all three concentrations resulted in a significant reduction of Vpu-deficient virus release 
to near or below detectable levels at both time points (figure 4.2).  At 72 h and 96 h, 100 
ng of Bst-2 was capable of reducing Vpu-deficient virus release 73% and 83%, 
respectively. However, the effects on wild-type virus were equally impressive as a 
reduction of 50-60% to 85-90% was observed at 72 and 96 hrs for cells co-transfected 
with 333 ng or 1 µg Bst-2 plasmid.   
The results obtained in these experiments indicated that SNAPIN expression 
resulted in a maximal decrease of Vpu-deficient virus of approximately 1-log.  
Interestingly, the effects of SNAPIN seemed to plateau at 96 hrs with relatively little 
variation being observed in COS7 cells co-transfected with 100 ng or 1 µg of plasmid.   
Furthermore, the antiviral activity of all 3 restriction factors increased at later time points 
indicating that a gradual build up of these factors leads to their increased antiviral 
activity. 
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Figure 4.2: The Expression of SNAPIN restricts Vpu-deficient virus in COS7 cells. 
Indicated amounts of BAP (negative control) or restriction factor plasmids were co-
transfected into COS7 cells with a constant amount of Vpu-deficient proviral DNA 
(Panels A and B) or wild type proviral DNA (Panels C and D) along with varying 
amounts of stuffer plasmid (empty pcDNA.3.1 vector) in order to obtain similar promoter 
units for each transfection.  Viral titers were determined by p24 ELISA at 72 and 96 hrs 
post transfection.  Results are averages of triplicate wells.  
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4.3 Co-transfection of wild type virus reduces SNAPIN expression 
In order to demonstrate the effects of SNAPIN were not specific for COS7 cells, 
and that the Vpu-dependent phenotype could be manifested in other normally permissive 
cells lines, similar experminets were conducted in 293Ts.  In addition, the maximal 
amount of SNAPIN was reduced in order to obtain a level of expression with minimal to 
no effect on wild-type levels.  Furthmore, additional plasmid concentrations were used to 
attempt to more accurately determine the range of SNAPIN expression capable of 
restricting Vpu-deficient virus. 
As figure 4.3a demonstrates, the expression of SNAPIN in 293Ts similarily 
reduces viral titer in a Vpu-dependent manner.  At a ratio of 1:8 SNAPIN to proviral 
DNA, a modest decrease in viral titer is observed.   However, in cells tranfected with a 
1:1 ratio of SNAPIN to proviral DNA, an 87% decrease in viral titer was observed.  
Importantly, no effect was observed on wild-type levels at this ratio while a dose-
dependent effect was clearly visible when cells were co-transfected with SNAPIN and a 
Vpu-deficient proviral clone. 
The same samples from figure 4.3a were then eximaned by Western Blotting.  
Virus in supernatants were pelleted through a 20% sucrose cushion and separated on 
SDS-PAGE gels along with cell lysates.  Anti-p24 blots revealed that cells lysates 
expressed a relatively constant level of p24/p55, yet the amount of virus in supernatant 
pellets varied according to the amount of SNAPIN co-transfected (figure 4.3, Panel B).  
p24 levels decreased in a dose-dependent manner in cells transfected with SNAPIN and 
Vpu-deficient proviral DNA but not when co-transfected with wild type proviral DNA.   
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Of particular interest, the analysis of SNAPIN levels in transfected cell lysates 
suggested that SNAPIN expression was reduced in lysates co-transfected with wild type 
virus (figure 4.3a, anti-FLAG panel).  In particular, SNAPIN seemed to be absent from 
lysates transfected with 50-200 ng of SNAPIN plasmid along with wild type proviral 
DNA.  However, when examining SNAPIN expression when co-transfected with a Vpu-
deficient proviral clone, SNAPIN expression was still evident.  This experiment provided 
the first evidence that Vpu target SNAPIN for degradation.  
In order to verify these results, the same experiment was once again conducted 
with samples generated from COS7 cells.  Indeed similar results were obtained as a 
significant decrease in SNAPIN expression levels became apparent at lower 
concentration levels (figure 4.4).  These results suggested that Vpu may target SNAPIN 
for degradation, and that the inability of SNAPIN to restrict wild type virus may be 
directly related to the expression of Vpu.  Furthermore, these experiments indicate that 
SNAPIN expression does not result in an accumulation of Vpu-deficient virions within 
the cell as no increase in the amount of p24/p55 was observed in cell lysates.   
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Figure 4.3: SNAPIN specifically restricts Vpu-deficient virus release and is 
degraded by Vpu in 293T cells. Panel A: p24 ELISA was used to determine viral titers 
of samples used for Western Blotting Analysis. Graph represents triplicate samples. Panel 
B: Virus from supernatants were pelleted through a 20% sucrose cushion and separated 
on a 14% SDS-PAGE gel along with cell lysates.  Viral proteins were detected using a 
αp24 monoclonal antibody.  αFLAG antibody was used to detect FLAG-SNAPIN levels 
while α−β-actin antibodies were used to normalize samples.  
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Figure 4.4: SNAPIN is degraded in a Vpu-dependent manner in COS7 cells.Virus 
from supernatants were pelleted through a 20% sucrose cushion and separated on a 14% 
SDS-PAGE gel along with cell lysates.  Viral proteins were detected using a αp24 
monoclonal antibody.  αFLAG antibody was used to detect FLAG-SNAPIN levels while 
α−β-actin antibodies were used to normalize samples. 
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Chapter V 
siRNA mediated knockdown of SNAPIN expression in non-permissive 
cell lines partially rescues Vpu-deficient virus release 
5.0 Chapter Summary 
According to figure 3.4, HeLa, macrophages, Jurkats and H9 cells all exhibit a 
Vpu-dependent phenotype.  Therefore, siRNA experiments were conducted to determine 
the effects of decreased SNAPIN expression in these cell lines.  As a control, the effects 
of siRNA targeting SNAPIN were also examined in three Vpu-independent cell lines.  
siRNAs targeting BST-2 were used for comparison and, in addition, were used in 
combination knockdown experiments targeting both SNAPIN and Bst-2. 
Results from these experiments indicated that targeting of SNAPIN in HeLa cells 
and macrophages resulted in a partial rescue of Vpu-deficient phenotype.  Since these 
cells are known to express Bst-2, the partial rescue observed is of significant interest.  
Furthermore, co-transfection of siRNAs targeting both SNAPIN and Bst-2 resulted in 
Vpu-deficient viral titers equivalent to wild type levels. 
Additional experiments in T-cell lines demonstrated that siRNA targeting 
SNAPIN increased Vpu-deficient viral titers to levels comparable with wild type viral 
titers. Interestingly, siRNA targeting Bst-2 had no significant effect on virus production 
in the T-cell lines examined in these experiments.  These results suggest that Bst-2 cannot 
be the sole cellular factor responsible for the Vpu-dependent phenotype.  Importantly, 
neither SNAPIN nor Bst-2 siRNAs had any effect on viral titers in normally permissive 
cell lines.   
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5.1 siRNA targeting SNAPIN partially rescues virus production in HeLa cells 
Pooled siRNAs targeting SNAPIN resulted in a greater than 90% knockdown in 
SNAPIN RNA in HeLa cells as determined by Real-time PCR.  The decreased expression 
of SNAPIN increased viral titers by 2.5 to 3.0-fold at 48, 72 and 96 hrs post transfection 
of proviral DNA (figure 3.4, Panel A).  Interestingly, a moderate increase was also 
observed in HeLa cells transfected with wild type proviral DNA (figure 3.4, Panel B).  
These results support the initial shRNA-HeLa experiments that identified SNAPIN as a 
putative factor involved in the Vpu-phenotype. 
When comparing the percentage of Vpu-deficient virus released compared to wild 
type, an average of approximately 20 to 30% viral titer is observed in HeLa cells 
transfected with scrambled RNA (negative control).  A similar ratio has been previously 
reported by several groups in HeLa cells, suggesting that siRNA transfection does not 
alter the ratio of viral production (109).  Vpu-deficient virus production is increased to 
roughly 60 to 70% of the levels of wild type virus when SNAPIN expression is decreased 
between 48 to 96 hrs post transfection (figure 5.1, Panel B).  
Pooled siRNA targeting Bst-2 increased viral titers by 3.0 to 3.5-fold and resulted 
in viral titers at maximum of 80% that of wild type titers.  These results are slightly  
higher than those obtained by previous studies that suggest decreased expression of Bst-2 
resulted in an increase in viral titers ranging between 65 to 75% of wild type levels or a 
2.5 to 3.0-fold increase in Vpu-deficient virus (73).  Decreased Bst-2 expression also 
increased wild type virus production in a similar range as that observed with decreased 
SNAPIN expression. 
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In comparing the relative increases in Vpu-deficient viral titers associated with 
the decreased expression of SNAPIN and Bst-2, Bst-2 resulted in an increase in viral titer 
of approximately 5 to 8% greater than SNAPIN.  The effect of knocking down Bst-2 
expression on wild type virus, however, was much more pronounced than in cells 
transfected with siRNA targeting SNAPIN.  Decreased Bst-2 expression resulted in an 
increase of between 20 to 30% in wild type viral titers. This suggests that the antiviral 
activity of Bst-2 is not specific for Vpu-deficient virus, as wild type virus is also partially 
restricted by Bst-2.  These results are consistent with previous expression experiments, in 
which increasing amounts of Bst-2 also resulted in decreased wild type viral titers (73).   
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Figure 5.1: siRNA targeting of SNAPIN in HeLa cells increases Vpu-deficient virus 
titers. Pooled siRNAs targeting SNAPIN and Bst-2 were transfected into HeLa cells 
along with control scrambled siRNAs.  After 48 hrs, cells were infected with equal 
amounts of VSV-G pseudotyped wild type or Vpu-deficient virus. Supernatants were 
collected at 24 hr time points for 5 days post-infection.  Viral titers were determined by 
p24 ELISA.  Panel A represent viral titers from Vpu-deficient samples while Panel B 
represent wild type viral titers.  The percentage of Vpu-deficient virus release compared 
to wild type is given in Panel C. Results are averages of triplicate samples. 
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5.2 Double siRNA transfections relieves restriction of Vpu-deficient  
virus release from Macrophages 
In order to determine the effects of SNAPIN down-regulation in physiologically 
relevant cells, similar siRNA experiments were performed in human macrophages. In 
general, macrophages transfected with scrambled siRNA produced 10 to 20% vpu-
deficient virus compared to wild type.  As figure 5.2A demonstrates, siRNA targeting 
SNAPIN in macrophages increased viral titers by approximately 6-fold. In comparing 
titers from wild type virus transfected with SNAPIN siRNA, Vpu-deficient virus 
production increased to 65% of wild –type levels.  These differences are clearly visible 
when supernatants and lysates were analyzed by Western blotting as previously described 
(figure 5.2, Panel B).   
The levels of Vpu-deficient virus released in the presence of siRNA targeting Bst-
2 reached approximately 77% of scrambled wild type levels (figure 5.2, Panel A). 
However, when comparing the effects of siRNA targeting Bst-2 on wild type and Vpu-
deficient virus production, Vpu-deficient virus reached 66% of wild type levels.  This 
was expected as previous experiments in HeLa cells indicated that Bst-2 knockdown 
increased wild type levels as well as Vpu-deficient virus.  Importantly, the percentage 
increase in wild type levels is more moderate in macrophages than HeLa cells.  This can 
most likely be attributed to previous findings that demonstrated that macrophages express 
significantly less Bst-2 than HeLa cells (figure 3.4, Panel C) (75).    
In these experiments, macrophages were also transfected with a combination of 
SNAPIN and Bst-2 pooled siRNAs (figure 5.2, Panel A and B).  Unexpectedly, the levels 
of Vpu-deficient virus greatly exceeded the amount of wild type virus released from the 
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combination of siRNAs.  Exactly why this surprise finding was consistantly observed 
over the course of several experiments is not well understood. Perhaps, the cellular 
trafficking of Gag in the presence of decreased SNAPIN and Bst-2 expression results in a 
in altered route of viral egress than normally occurs in the presence of Vpu.  Nonetheless, 
the finding that an additive effect is observed when SNAPIN and Bst-2 expression are 
decreased in combination, suggests that two independent antiviral pathways exist.  This 
possibility is discussed in greater detail in Chapter VII.  
The results obtained from these siRNA experiments suggested that decreased 
expression of SNAPIN could partially rescue Vpu-deficient virus production in cells 
known to express Bst-2. However, the effects of SNAPIN in cell lines that exhibited a 
Vpu-dependent phenotype in the absence of Bst-2 expression were unknown.  Therefore, 
siRNA experiments were conducted in two T-cell lines previously reported to express 
little to no Bst-2, Jurkats and H9 cells.  
5.3 Decreased expression of SNAPIN, but not Bst-2, alleviates the  
Vpu-dependent phenotype from T-cell lines 
 
As demonstrated in figure 5.3, two siRNA pools targeting SNAPIN in Jurkat cells 
nearly completely rescued Vpu-deficient viral production to levels similar to wild type 
titers. Scrambled siRNA demonstrated that only 20 to 30% of Vpu-deficient virus was 
released in Jurkat cells (Panels A and B).  However, siRNAs targeting SNAPIN increased 
viral titers to levels approximately equal to wild type viral titers at both 48 and 72 hr time 
points (P < 0.05).  Importantly, wild type levels remained relatively unchanged in 
samples with decrease SNAPIN expression levels. 
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Figure 5.2: Transfection of SNAPIN siRNA increases Vpu-deficient virus release in 
macrophages. siRNAs targeting SNAPIN, Bst-2 or in combination were transfected into 
macrophages. Forty-eight hours post-transfection, macrophages were infected with wild 
type or Vpu-deficient virus.  Supernatants were collected 48 hrs post infection and viral 
titers were determined using p24 ELISA (Panel A) or Western Blotting (Panel B) as 
previously described. 
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Perhaps the most intriguing finding of these experiments was the determination 
that Bst-2 had little to no effect on viral production in Jurkats as no statistical significance 
was observed when compared to cells transfected with control siRNA (figure 5.3). 
Furthermore, the combinatorial effect that had been observed in macrophages co-
transfected with siRNAs targeting both SNAPIN and Bst-2 was completely absent in 
Jurkat cells. While these results were expected, as Jurkats do not express Bst-2, the 
finding that decreased SNAPIN expression could alleviate the Vpu-phenotype nearly 
completely on its own strongly suggests that SNAPIN is a key cellular factor in 
restricting Vpu-deficient virus release (figure 5.3, Panel A-C).  
Similar results were observed in H9 cells, which similar to Jurkats, do not express 
Bst-2 (75).  H9 cells transfected with scrambled siRNA produced approximately 30% 
Vpu-deficient virus compared to wild type (figure 5.4).  However, H9 cells transfected 
with SNAPIN siRNAs produced Vpu deficient virus in a similar range to the viral titers 
released from cells infected with wild type virus.   
As previously determined in Jurkats, the yield of Vpu-deficient virus from H9 
cells transfect with siRNA targeting Bst-2 did not increase.  Similarly, no additive 
increase in viral titers was observed when H9 cells were co-transfected with siRNA 
targeting both SNAPIN and Bst-2.  In addition, wild type viral titers were not affected by 
transfection of siRNAs targeting SNAPIN or Bst-2.  
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Figure 5.3: siRNA mediated knockdown of SNAPIN in Jurkats increases Vpu-
deficient virus release. Jurkats were transfected with siRNAs targeting SNAPIN, Bst-2 
or both.  After 48 hrs, siRNA transfected cells were infected with equal amounts of VSV-
g pseudotyped wild type or vpu-deficient virus. Viral titers were determined at 48 hrs 
(Panel A) and 72 hrs (Panel B).  Supernatant from 72 hr time point and lysates were 
separated on 14% SDS-PAGE gel and blotted with αp24 antibody and normalized using 
an anti-β-actin antibody (Panel C).  Bars marked SNAPIN A and D represent results from 
two different siRNA pools.  
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The finding that siRNA targeting SNAPIN alone could rescue Vpu-deficient virus 
to 70 to 75% of wild-type suggests that Bst-2 is not the sole cellular restriction factor 
countered by Vpu in HeLa and macrophages.  Furthermore, siRNA analysis of Jurkats 
and H9 cells, clearly demonstrated that decreased expression of SNAPIN resulted in 
levels of Vpu-deficient virus release that were nearly equivalent to the amount of wild 
type virus released. Conversely, no significant increases in viral titers were observed 
when Jurkats or H9 cells were transfected with siRNAs targeting Bst-2. 
5.4 siRNAs targeting SNAPIN and/or Bst-2 have no effect on non-permissive  
cell lines 
 
In order to verify that the effects of SNAPIN expression only corresponds with 
cell lines that possess a Vpu-phenotype, siRNA experiments were also conducted in three 
Vpu-independent cell lines. As indicated in figure 5.5, neither siRNAs targeting SNAPIN 
or Bst-2 had any effect on Vpu-deficient or wild type virus production in COS7, HOS or 
293Ts.  These results were expected as previous reports have indicated that these cell 
lines do not require Vpu for efficient virus release.   
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Figure 5.4: siRNA targeting SNAPIN increases Vpu-deficient virus release in H9 
cells. H9 cells were transfected with siRNAs targeting SNAPIN, Bst-2 or both.  After 48 
hrs, cells were infected with an equal amount of VSV-G pseudotyped wild type or vpu-
deficient virus.  Viral titers were determined by p24 ELISA 48 hrs after infection.  
Pelleted virus and lysates were separated on 14% SDS-PAGE gel and blotted with αp24 
antibody and normalized using an anti-β-actin antibody (Panel B).   
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Figure 5.5: siRNA targeting either SNAPIN or Bst-2 has no effect on Vpu-
independent cell lines. Vpu-independent cell lines were transfected with siRNAs 
targeting SNAPIN, Bst-2 or both.  After 48 hrs, cells were infected with VSV-G 
pseudotyped wild type or Vpu-deficient virus.  Viral titers were determined by p24 
ELISA 72 hrs after infection.  Panel A – COS7; Panel B – HOS; Panel C – 293Ts. 
Results are average of triplicate wells. 
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Chapter VI 
Co-expression of HIV-1 and SIVCPZ Vpu decreases SNAPIN expression 
6.0 Summary 
 
 Previous experiments indicated that Vpu may directly target SNAPIN for 
degradation; however, the exact mechanisms were unknown. These findings were first 
verified by co-transfection of a SNAPIN expression construct with Vpu.  Using this 
method, a dose-dependent decrease in SNAPIN expression levels was observed when 
increasing concentrations of Vpu were co-transfected. Similar findings were observed in 
experiments using SIVCPZ Vpu expression constructs. 
 Furthermore, the co-transfection of increasing amounts of wild type HIV-1 
proviral DNA decreased SNAPIN expression, whereas, the co-transfection of Vpu-
deficient proviral DNA did not alter SNAPIN expression levels. This suggests that Vpu 
in the context of a provirus is also capable of targeting SNAPIN for degradation. In 
contrast, HIV-2 did not decrease SNAPIN levels possibly indicating that the degradation 
of SNAPIN is a Vpu-specific phenotype.  
In order to determine the mechanisms by which Vpu targets SNAPIN for 
degradation, proteosomal and lysosomal inhibitors were added to cells after transfection. 
The results from these experiments suggest that Vpu may target SNAPIN for degradation 
using both the proteasome and lysosomal degradation pathways.  In general, a greater 
increase in the overall amount of SNAPIN was observed when cells were treated with 
lysosomal inhibitors. In addition, translation inhibition assays demonstrated that Vpu 
significantly increases the rate of SNAPIN turnover.    
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6.1 Co-transfection of Vpu decrease SNAPIN expression in a dose dependent 
manner. 
 As observed in Chapter IV, co-transfection of wild type virus appeared to reduce 
the amount of SNAPIN expression when compared to co-transfection of SNAPIN with 
Vpu-deficient proviral DNA.  In addition, early attempts to demonstrate a physical 
interaction between Vpu and SNAPIN using immunoprecipations revealed that when 
SNAPIN was co-transfected with Vpu, a significant decrease in SNAPIN expression was 
observed.  These results suggested that Vpu expression may negatively regulate SNAPIN 
expression. 
 In order to determine whether Vpu could directly lead to a reduction in SNAPIN 
expression, several experiments were conducted in which a constant amount of FLAG-
tagged SNAPIN were co-transfected with increasing amounts of Vphu.HA.  As 
demonstrated in figure 6.1a, SNAPIN expression was significantly reduced in wells co-
transfected with increasing amounts of Vphu.HA.  The reduction of SNAPIN occurred in 
a dose-dependent manner suggesting that a direct relationship between levels of Vpu 
expression and the rate of degradation existed.   
 In wells transfected with a constant amount of Vphu.HA and increasing amounts 
of FLAG-SNAPIN, a similar defect was observed (figure 6.1, right side of panel A).  
Lower concentrations of FLAG-SNAPIN were not detected, while SNAPIN was only 
detected in wells transfected at a 3:1 ratio of FLAG-SNAPIN to Vphu.HA.  These results 
also demonstrate that while Vpu leads to the degradation of SNAPIN, the expression of 
SNAPIN does not reduce the amount of Vpu.  This experiment suggests that the decrease 
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in SNAPIN expression levels is specifically due to Vpu function and that Vpu is not 
turned over during the course of SNAPIN degradation.  
 In order to further demonstrate that the Vpu-dependent degradation of SNAPIN 
was a specific occurrence, several control experiments were conducted.  In the first 
experiment, the issue of competitive promoter decreases was addressed by co-
transfecting all wells in figure 6.1, panels B to D, with equal amounts of promoter units.  
As observed in figure 6.1c, FLAG-SNAPIN expression was not affected by co-
transfection of increasing amounts of empty vector. Importantly, co-transfection of 
pcDNA.3.1-Vphu.HA with FLAG-tagged BAP had no affect on BAP expression.  Taken 
together, these results indicate that Vpu specifically targets SNAPIN for degradation.     
6.2 Wild type HIV-1 and SIVCPZ reduces SNAPIN expression 
 To determine the extent of which SNAPIN is targeted for degradation by other 
primate lentiviruses, expression constructs encoding Vpu homologues of 
phylogenetically related strains of SIV were tested.  Unlike the majority of SIV strains, 
SIVCPZ encodes a Vpu-gene with similar amino acid sequence and functional properties 
as those observed with HIV-1 Vpu.  Therefore, two Vpucpz expression constructs were 
used in co-transfection experiments to determine whether SNAPIN degradation was a 
functional property of Vpu. 
 As previously demonstrated, co-transfection of empty pcDNA3.1 vector has no 
effect of FLAG-SNAPIN expression levels (figure 6.2a).  However, co-transfection of 
HIV-1 Vphu.HA had a similar effect to that observed in figure 6.1a and b, with a gradual  
90 
 
 
 
 
Figure 6.1: Vpu decrease SNAPIN expression in a dose-dependent manner. Panel A: 
Equal amount of FLAG- SNAPIN plasmid were co-transfected with increasing amounts 
of pcDNA3.1-Vphu.HA (left) and equal amounts of pcDNA3.1-Vphu.HA were co-
transfected with increasing amounts of FLAG-tagged SNAPIN. Similar to panel A, a 
constant amount of FLAG-tagged SNAPIN (200 ng) was co-transfected into 293Ts along 
with 0.14, 0.5 or 1.38 µg of pcDNA3.1-Vphu.HA (Panel B) or empty pcDNA3.1 vector 
(Panel C) in addition to stuffer plasmid.  As a control, constant amounts of BAP were co-
transfected with increasing amounts of pcDNA3.1-Vphu.HA to demonstrate the 
specificity of degradation (Panel D).  Five percent of lysates were separated on 14% 
SDS-PAGE gels prior to blotting with anti-FLAG, anti-HA and anti-β-actin antibodies.   
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Figure 6.2 : SNAPIN is degraded by HIV-1 and SIVCPZ Vpu. 293Ts were co-
transfected with equal amounts of FLAG-SNAPIN (200 ng) and 0, 50, 100, 200, 400 or 
800 ng of empty pcDNA3.1 vector (Panel A), pcDNA3.1-Vphu.HA (Panel B), or SIVCPZ 
Vpu expressing vector (Panel C and D) in addition to empty expression plasmid to obtain 
equal promoter units per well.  Five percent of lysates were separated on 14% SDS-
PAGE gels prior to blotting with anti-FLAG, anti-HA and anti-β-actin antibodies.   
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decrease in FLAG-SNAPIN being observed with increased Vphu.HA expression.  These 
results indicated that nearly all FLAG-SNAPIN was degraded when an equal 
concentration of pcDNA3.1-Vphu.HA was co-transfected with FLAG-SNAPIN (figure 
6.2b).   
 Interestingly, the co-transfection of both SIVCPZ vpu clones resulted in the gradual 
decrease of FLAG-SNAPIN.  The rate of decrease was similar to that observed when 
293Ts were co-transfected with HIV-1 Vpu, however, a slight delay was observed.  
Whereas, HIV-1 Vpu nearly completely reduced SNAPIN expression at a 1:1 ratio, both 
SIVCPZ Vpu clones seemed to decrease SNAPIN expression with a decreased efficiency 
as FLAG-SNAPIN was clearly still detectable at a 1:2 ratio.  
 This is not entirely surprising as these experiments were conducted in a human 
cell line (293Ts) and using a SNAPIN expresion construct encoding the human SNAPIN 
sequence.   The decreased efficiency of SIVCPZ encoded Vpu may result from its inablity 
to sufficeintly harness the cellular machinery required for the down-regulation of 
SNAPIN.  Nonetheless, these findings confirmed that the degration of SNAPIN was a 
specific function of Vpu.   
 Unlike HIV-1 and SIVCPZ, the majority of SIV strains as well as HIV-2 do not 
express a Vpu-homologue.  Therefore, the effects of HIV-2 on SNAPIN expression were 
determined  and compared with wild type HIV-1, Vpu-deficient HIV-1 and two SIVCPZ  
strains using full-length infectious proviral clones.  As demonstrated in figure 6.3a, wild 
type HIV significantly decreased the amount of FLAG-SNAPIN detected as the amount 
of proviral DNA co-transfected increased.  Conversly, the co-transfection of Vpu-
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deficient proviral DNA had essentially no effect on SNAPIN expression levels regardless 
of nearly equal transfection efficiencies (based on p24/p55 levels).  These experiments 
provided clear and concise evidence that Vpu-expression in the context of proviral 
expression of Vpu could target SNAPIN for degradation.  While SNAPIN degradation 
was again observed in cells expressing SIVCPZ1.69 or SIVCPZ3.1proviral DNA, co-
transfection of HIV-2 had no effect on SNAPIN expression levels (figure 6.3, panels B to 
D).   
Since HIV-2 does not express Vpu, this was not entirely unexpected.  One 
possiblity is that HIV-2 is simply not attenuated by SNAPIN expression.  HIV-1 and 
SIVCPZ have specifically evolved a Vpu-gene, and perhaps SNAPIN inhibits these 
lentiviruses specifically.  This possiblity and other potential implications of these 
experiments are further discussed in Chapter VII.    
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Figure 6.3: Wild type HIV-1 and SIVCPZ degrade SNAPIN. 293Ts were co-transfected 
with equal amounts of FLAG-tagged SNAPIN (200 ng) along with 0, 100, 200, 400, 800 
or 1600 ng of the indicated proviral constructs.  Panel A represent Western Blot analysis 
of wild type  (left) and Vpu-deficient HIV-1 (right).  Panel B represent results from HIV-
2 co-transfection while panels C and D represent Western Blots analysis of two SIVCPZ 
strains.  Five percent of lysates were separated on 14% SDS-PAGE gels prior to blotting 
with anti-FLAG, anti-p24 and anti-β-actin antibodies.   
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6.3 Proteasome and Lysosome Inhibitors prevent SNAPIN degradation 
 In order to determine the mechanisms involved in Vpu-mediated degradation of 
SNAPIN, proteasome and lysosome inhibitors were added to cells 24 hrs post co-
transfection of FLAG-SNAPIN and Vphu.HA.  Western blot analysis revealed that the 
decrease in FLAG-SNAPIN expression normally observed by the addition of increasing 
amounts of Vphu.HA was not altered by the addition of DMSO to the culture media.   
 The efficiency of proteasome inhibition was determined by blotting for tumor 
suppressor protein, p21.  Under normal conditions, p21 expression levels are kept to 
nearly undetectable levels through continuous degradation via the proteasome pathway.  
Therefore, previous publications have used p21 expression levels as a marker for 
determining the efficiency of proteasome inhibition (110).  In addition, cyclin T1 was 
used as a loading control since its expression levels are not altered by the presence of 
proteasome or lysosomal inhibitors.  
 Interestingly, the addition of both proteasome and lysosome inhibitors prevented 
the degradation of SNAPIN (figure 6.4).  Cells treated with MG132, a proteasome 
inhibitor, prevented the degradation of SNAPIN regardless of increasing concentration of 
Vpu. Levels of SNAPIN remained constant when compared to SNAPIN expression when 
co-transfected with empty vector.  Further experiments were conducted to determine if 
Vpu-mediated degradation occurred through ubiquitination, however, inconclusive 
results were obtained.  
While proteasome inhibition prevented degradation of SNAPIN, the effects of 
lysosomal inhibitors not only protected SNAPIN from degradation, but also led to a 
96 
 
significant increase in the overall amount of SNAPIN expressed.  An estimated 4 to 5 
fold increase in SNAPIN expression levels was observed when either chloroquine or E-
64 was added to transfected cells (figure 6.3, anti-FLAG panel).  Since SNAPIN is 
known to be involved in the trafficking of cellular proteins to lysosomes, these findings 
suggest that Vpu’s interaction with SNAPIN may result in SNAPIN itself being targeted 
for lysosomal degradation.   
Of further interest was the observation that both proteasome and lysosome 
inhibitors resulted in increased Vphu.HA expression (figure 6.3, anti-HA panel).  These 
results suggest that SNAPIN and Vpu turnover may occur through similar mechanisms.  
Previous reports have demonstrated that Vpu degradation may occur through either 
degradation pathway, verifying the results obtained in these experiments (111).  
Furthermore, these experiments identify the possible pathways involved in Vpu-mediated 
degradation of SNAPIN. 
6.4 Vpu increases the rate of SNAPIN turnover 
 To demonstrate that Vpu reduces SNAPIN expression at the protein level as 
opposed to transcriptional repression, the rate of SNAPIN turnover was determined using 
a translation inhibition assay.  Briefly, cells were co-transfected with equal amounts of a 
FLAG-SNAPIN-IRES-GFP construct and pcDNA3.1-Vphu.HA or empty pcDNA3.1 
vector.  Twenty-four hours after transfection, spent media was replaced with fresh media 
containing 10 µM cyclohexamide to inhibit cellular translation.   
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Figure 6.4: Both Proteasome and Lysosomal Inhibitors prevent Vpu-mediated 
degradation of SNAPIN. 293Ts were transfected with equal amounts of FLAG-tagged 
SNAPIN along with 0, 100, 200 or 400 ng of pcDNA.3.1a-Vphu.HA expression plasmid.  
24 hrs after transfection, culture media was replaced with complete media containing 10 
µM MG132 proteasome inhibitor, 20 µM chloroquine or 10 µM E-64.  Media containing 
the solvent, DMSO, was used as a control.  Lysates were collected 24 hrs after media 
containing inhibitors was added. Five percent of lysates were separated on 14% SDS-
PAGE gels prior to blotting with anti-FLAG, anti-p24 and anti-β-actin antibodies.  *p21 
can be detected in all samples with overnight exposure.   
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As determined by Western Blotting, SNAPIN expression was only modestly 
reduced over a 12 hour time period when co-transfected with empty pcDNA3.1 vector 
(figure 6.5).  This suggests that SNAPIN has a relatively slow turnover rate under normal 
conditions.  The difference, however, was quite substantial when SNAPIN was co-
expressed with Vpu.  From the initial time point (0 h), a significant decrease in SNAPIN 
expression was clearly evident.  This suggests that over the 24 hr period, prior to the 
addition of cyclohexamide, a substantial amount of SNAPIN has already been degraded 
by Vpu.  By 4 hrs, SNAPIN expression was nearly undetectable providing clear evidence 
that the rate of SNAPIN turnover was substantially increased in the presence of Vpu. 
 Densitometry analysis determined that the rate of SNAPIN turnover increased 
from approximately 8-12 hrs to 0-2 hrs.  These experiments, in addition to previous 
results, clearly demonstrate that Vpu specifically targets SNAPIN for degradation.  
However, the exact mechanism by which SNAPIN expression inhibits Vpu-deficient 
virus release remains to be determined.  
6.5 Protease treatment indicates that virions are not tethered to the plasma 
membrane 
 In an effort to determine whether virions remain “tethered” to the plasma 
membrane in a manner similar to the presumed antiviral mechanism of Bst-2 restriction, 
cells were treated with proteases as previously described (72).  In order to determine 
whether Bst-2 does indeed tether virions to the plasma membrane of Jurkat cells, cells 
were transfected with siRNAs targeting Bst-2.   
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Figure 6.5: Vpu-mediated decrease of SNAPIN expression occurs post-translational. 
Equal amounts of FLAG.SNAPIN.IRES-GFP and pcDNA3.1-Vphu.HA were co-
transfected into 293Ts.  After 24 hrs, fresh media containing 10 µM cyclohexamide was 
added to transfected cells to inhibit cellular translation.  Cells were harvested 
immediately after the addition of cyclohexamide (0 hr) and collected at 2, 4, 8 and 12 hrs.  
Cells were then lysed in RIPA buffer prior to separation on a 14% SDS-PAGE gel.  
Western blot analysis was conducted using αFLAG, αΗΑ and α-β-actin antibodies as 
described in the Material & Methods section. 
 
 
 
 
 
 
 
100 
 
The results obtained in these experiments, however, did not correspond with 
results previously published by Neil et al (97).  No significant increase in viral titers was 
observed by p24 ELISA or Western Blotting analysis of scrambled siRNA transfected 
cells infected with wild type virus or Vpu-deficient virus (figure 6.6, panel A).  This 
suggests that the retention of virions at the plasma membrane does not occur in Jurkat 
cells as previously suggested.  Since Jurkats do not express Bst-2 at the plasma 
membrane, these results were not entirely unexpected.   
 As previously demonstrated, siRNA targeting SNAPIN increased the amount of 
Vpu-deficient virus released.  Unexpectedly, siRNAs targeting Bst-2 increased the 
constitutive amount of virus released slightly above levels observed when wild type 
infected cells were treated with buffer alone.  However, this increase was not 
significantly over buffer treatment levels, and therefore, the slight increase in p24 levels 
was likely due to experimental error.   
 In order to verify previous results that suggested that the expression of Bst-2 
results in the retention of virions at the plasma membrane in 293Ts, similar transfection 
experiments were conducted (72).   While 293Ts expressing Bst-2 did seem to retain a 
protease-sensitive population of virions, viral antigen was also detected in buffer and 
subtilisin treated samples from 293Ts transfected with a control BAP plasmid (figure 6.6; 
left and right panels).  It is unclear whether the p24 levels detected in these samples were 
a result of incomplete removal of supernatants prior to buffer/subtilisin treatment, 
however, a slight increase in p24 levels was detected when BAP expressing cells were 
treated with subtilisin in both wild type and Vpu-deficient virus samples.   
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 Of note, a faint band was also detectable when wild type transfected, Bst-2 
expressing 293Ts were treated with subtilisin.  Since previous experiments indicated that 
Bst-2 was also capable of impeding wild type viral egress, albeit at a decreased efficiency 
than Vpu-deficient virus, this result was expected.  These results are further supported by 
a recent publication that demonstrated that 293Ts co-transfected with Bst-2 and either 
wild type or Vpu-deficient viral clones are both equally protease sensitive (112).  
Importantly, absolutely no detectable increases in viral titers were observed when 
SNAPIN transfected cells were treated with subtilisin (figure 6.6; middle panel).  This 
suggests that decreases in Vpu-deficient viral titers are not due to retention of virions at 
the plasma membrane as previously proposed for Bst-2.  Moreover, these results further 
demonstrate that the Vpu-dependent phenotype observed in Jurkats is not due to Bst-2’s 
antiviral activity.   
  
 
 
 
 
 
 
102 
 
 
 
Figure 6.6: Subtilisin treatments of infected Jurkats and transfected 293Ts. Jurkats 
transfected with siRNAs targeting SNAPIN or Bst-2 were infected with VSV-G 
pseudotyped wild type or Vpu-deficient virus 48 hrs post-transfection.  Supernatants were 
collected 72 hrs post-infection while half the total cells were treated with either buffer or 
buffer containing 1 mg/ml subtilisin (Panel A).  After 30 m, 500 µl of complete media 
was added to treated cell lysates to inhibit protease activity.  p24 levels were measured by 
p24 ELSIA and examined by Western Blot analysis.  Samples were centrifuged to collect 
cells and viruses in supernatants were pelleted through a 20% sucrose cushion while cells 
were lysed in RIPA buffer.  Virus pellets and lysates were examined by Western Blotting 
using anti-p24 monoclonal antibodies.  Panel B: 293Ts were co-transfected with SNAPIN 
or Bst-2 constructs along with wild type or Vpu-deficient virus as previously described.  
Samples were analyzed by Western blotting as in Panel A.  C = Constitutive; B = Buffer 
only; S = Buffer + Subtilisin.   
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CHAPTER VII 
Discussion: Working towards a SNAPIN/Bst-2 Model 
7.1 A new paradigm in Bst-2’s antiviral activity  
The current model of virus restriction by Bst-2 involves the tethering of virions to 
the plasma membrane, which are subsequently internalized via the process of endocytosis 
(72).  Indeed several groups have demonstrated that the expression of Bst-2 in otherwise 
permissive cells results in what appears to be the retention of virions at the plasma 
membrane and intracellular vesicles.  However, Western Blot analysis used to visualize 
the total intracellular amounts of p24/p55 demonstrates that there is no increase in the 
amounts of intracellular virions between wild-type and Vpu-deficient virus.  While it can 
be argued that variations in the amount of virus retained intracellularily and at the plasma 
membrane cannot be readily discerned by Western Blot, previously published subtilisin 
digestion experiments have demonstrated that the two subsets of p24/p55 can be 
distinguished (72).  
Prior to the discovery of Bst-2, researchers demonstrated that subtilisin treatment 
of 293Ts resulted in the release of both wild type and Vpu-deficient virions (Figure 7.1, 
panel A) (97).  Since 293Ts do not express Bst-2 in the absence of IFN induction, this 
finding suggests that virions remain attached to the plasma membrane in the absence of 
Bst-2 by other protease sensitive cellular factors (72, 75).  However, once the antiviral 
activity of Bst-2 was identified, Neil et al would then suggest that only when 293Ts were 
transfected with tetherin, would subtilisin treatment release tethered virions (Figure 7.1, 
panel B) (72).  
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Figure 7.1: Subtilisin treatment releases protease sensitive virions in the absence of 
Bst-2 expression. 293Ts transfected with wild type or Vpu-deficient proviral DNA were 
subject to subtilisin treatment to remove virions attached to the plasma membrane (Panel 
A).  In the absence of IFN-treatment or Bst-2 expression, 293Ts appear to retain virions 
at the plasma membrane that is protease sensitive (unmodified figure; ). Panel B: 293Ts 
expressing Bst-2 does not appear to retain virions more efficiently than non-transfected 
293Ts cells (unmodified figures; ref. 97 and 72). 
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Furthermore, subtilisin treatment of wild type or Vpu-deficient virus infected 
Jurkats did not result in the accumulation of significantly variable amounts of protease 
sensitive virions being released from the plasma membrane (97).  In these experiments, 
subtilisin digestion of Bst-2 transfected 293Ts did appear to release a minor amount of 
‘tethered’ virions, however, subtilisin treatment of 293Ts transfected with BAP also 
seemed to release attached virions.  Since previous reports have determined that Jurkats 
do not express Bst-2 at the plasma membrane, the concept of Bst-2 ‘tethering’ virions at 
the plasma membrane is debatable (72, 74, 75).   
The presence of internal aggregates upon transfection of Gag-GFP constructs into 
HeLa cells has also been recently attributed to Bst-2’s antiviral activity (72).  The 
authors, who first identified Bst-2, have suggested that Bst-2 tethers virions to plasma 
membrane and that aggregates form as a result of the endocytosis of tethered virions 
(106, 113).  However, as demonstrated in chapter III, the presence of internal aggregates 
cannot be attributed to a Vpu-dependent phenotype as aggregates are clearly visible in 
COS7 cells, which do not have a Vpu-dependent phenotype (107).  In addition, the same 
authors previously demonstrated that although internal aggregates are observed in HeLa 
cells and primary macrophages, they are also observed in 293Ts, albeit in 38% of cells 
versus 58% in macrophages (106).   
Recent studies suggested that when over-expressed, tagged Bst-2 can be detected 
by Western Blotting virions pelleted through a sucrose gradient (97).  However, this is 
contrary to previous reports that determined that endogenous Bst-2 is not detected in 
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virions harvested from HeLa cells (75).  Since HeLa cells express the highest levels of 
Bst-2, the likelihood of Bst-2 incorporation into virions is unlikely.   
The same study that determined virion incorporation of Bst-2 also suggested that 
Bst-2 associates with budding virions at the plasma membrane. However, these 
experiments used HIV-1 Gag with a mutation in the PTAP L domain (97).  The use of 
this mutant blocks viral budding before completion and produces scanning electron 
microscope images that suggest Bst-2 and budding virions associate at the plasma 
membrane.   
However, these results are subjective as no differences in association are observed 
when either a transmembrane or GPI mutant of Bst-2 is co-expressed with the PTAP-Gag 
mutant (97).  Furthermore, the results indicated that there was no apparent enrichment of 
Bst-2 to the site of viral budding. The expression of a completely irrelevant plasma 
membrane molecule would likely lead to a similar, non-specific ‘association’ with 
budding virions.  Further examination of the mechanism of Bst-2’s antiviral activity is 
clearly required and should include experimentation of alternative hypothesis that are not 
solely related to the current tethering model. 
While Bst-2 clearly acts as a potent inhibitor of virus release, the finding that Bst-
2 expression is relatively limited in HIV-1 relevant cell lines and primary cells suggests 
that Bst-2 cannot be the sole factor responsible for the Vpu-phenotype (75).  Indeed, Bst-
2 possesses potent antiviral activity when expressed ectopically, yet the levels of 
restriction by endogenous Bst-2 would suggest a more moderate effect.  siRNA/shRNA 
experiments have shown that the knockdown of Bst-2 only partially rescues Vpu-
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deficient virus release (73).  Furthermore, as demonstrated in figure 3.4, there is 
absolutely no correlation between Bst-2 expression levels and the extent of the Vpu-
dependent phenotype observed (75).   
One recent finding suggests that the structure of Bst-2, rather than the actual 
amino acid sequence of Bst-2, is responsible for its antiviral function (74).  In these 
studies a completely artificial Bst-2-like protein was expressed that included the N-
terminus domain of transferrin receptor, a mid-region of DMPK and a C-terminus 
domain of uPAR that included the GPI anchor domain (74). Interestingly, the expression 
of the artificial Bst-2 inhibited Vpu-deficient virus as efficiently as wild-type Bst-2.   
 Surprisingly, the artificial Bst-2 still maintained a Vpu-dependent phenotype as 
wild-type virus levels were significantly greater than Vpu-deficient virus levels (figure 
7.2). This is at odds with previous reports that suggest the N-terminus of Bst-2 is required 
for interaction with Vpu (103).  While the overall amount of wild-type virus released was 
less than control cells expressing wild-type Bst-2, Western Blots of lysates clearly 
demonstrated that the artificial Bst-2 was expressed at significantly higher levels than 
wild-type Bst-2 (74).  One possible reason for this observation is that the artificial Bst-2 
is not recognized by cellular proteins involved in the turnover of membrane proteins or 
that artificial Bst-2 is simply turned over at a slower rate than wild-type Bst-2.   
 Regardless of the turnover rate, the finding that a Vpu-dependent phenotype still 
exists in the presence of artificial Bst-2 suggests that Bst-2’s antiviral activity may 
potentially be overcome by Vpu in an indirect manner and without the direct interaction 
between both proteins.  This leads to the possibility that Vpu alters the trafficking of 
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virions directly away from plasma membrane regions high in Bst-2 expression or that 
perhaps Vpu inhibits a cellular pathway such as the exosome pathway, enabling virion 
release.  
It has also been suggested that IFN-induced expression of Bst-2 in normally 
permissive cell lines or Vpu-dependent cell lines has no effect on wild type virus titers 
(103).  This is somewhat confounding for two reasons; first, the experiments conducted 
in chapter III clearly demonstrate that Bst-2 expression does indeed reduce wild type 
viral titers in addition to Vpu-deficient virus; and secondly, these experiments, in addition 
to previously published studies, have demonstrated that IFN-treatment significantly 
impairs wild type virus infection at multiple stages of the viral life-cycle (108). 
Recent publications have demonstrated that, contrary to initial reports, wild type 
virus is also reduced by the expression of nanogram quantities of Bst-2 expression 
plasmid (79, 80).  As indicated in figure 7.3, the transfection of 20 ng of Bst-2 expression 
plasmid in 293Ts reduces wild type virus by nearly 1-log (79).  Vpu-deficient virus, 
however, is reduced by approximately 1.5-logs. When examining the relative decrease in 
other cells lines, it is clearly evident that both wild type and Vpu-deficient virus 
production is significantly impaired by the expression of Bst-2 (79).  The maximal 
difference observed between wild type and Vpu-deficient virus is between 8 to 10-fold.   
Furthermore, when taken into account that viral titers were determined using 
TZM-Bl cells, the actual difference between wild type and Vpu-deficient viruses is likely 
further reduced.  As indicated in figure 7.3, HeLa cells were shown to have over a 10-
fold difference between wild type and Vpu-deficient virus production when viral titers 
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are measured using TZM-Bl cells.  However, as demonstrated in chapter V, p24 ELISA 
analysis of supernatants from HeLa cells generally results in a more modest 2.5 to 3.5-
fold difference of Vpu-deficient to wild type virus production.  This range of wild type to 
Vpu-deficient viral titers in HeLa cells and various other cell lines has previously been 
reported and are consistent with the ranges observed in these experiments (109). 
Furthermore, recent publications have also determined that expression of Vpu 
does not result in significant variation on the total cellular content of Bst-2 or its removal 
from the plasma membrane in most cells (75, 79, 112).  Interestingly, a modest down-
regulation has been reported in the two cell lines that express the most Bst-2, HeLa and 
CEMx174 cells (73, 75). However, initial experiments by Neil et al, demonstrated that 
Vpu had no effect on Bst-2 levels, plasma membrane localization or cellular distribution 
in HeLa cells (72). While the reasons for the discrepancies have yet to be determined, the 
finding that Vpu promotes viral egress in the absence of Bst-2 down-regulation is 
intriguing.   
In all likelihood, Bst-2 plays an important role in innate antiviral defenses against 
enveloped viruses in general.  While it is tempting to speculate that Vpu’s primary 
function is to counteract Bst-2 in the presence of an IFN response, siRNA mediated 
knockdown of Bst-2 did not alleviate the reduction of virion production when 
macrophages were co-cultured in the presence of IFNα.  This is not entirely surprising as 
TRIM22 (STAF50) has previously been shown to potently inhibit viral replication by 
inhibiting transcriptional activity from the HIV-LTR (114).   
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Figure 7.2: An artificial Bst-2 (teth.) restricts HIV-1 in a Vpu-dependent manner. 
An artificial Bst-2 construct composed of regions similar to wild type Bst-2 is capable of 
restricting HIV-1 in a Vpu-dependent manner. Boxed lanes on bottom panels reveal a 
Vpu-dependent phenotype even in the presence of an artificial Bst-2 construct.  Black 
arrows indicate the variation in expression level of wild type and artificial Bst-2 that lead 
to a reduced Vpu-dependent phenotype (unmodified figure; ref.74).    
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Figure 7.3: Expression of Bst-2 results in the reduction of both wild type and Vpu-
deficient HIV-1. One microgram of wild type or Vpu-deficient virus was co-transfected 
with 20 or 100 ng of human Bst-2 expression plasmid.  The amount of virus released 
from the indicated cell lines were quantified using TZM-Bl cells. As a control for Vpu-
phenotype, wild type and Vpu-deficient viral titers produced from HeLa cells were also 
determined using TZM-Bl cells (79). 
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7.2 Bridging the gap between Gag, SNAPIN and Vpu 
The putative role that SNAPIN may have in inhibiting viral egress may range 
from an alteration of Gag trafficking to a competition effect of SNAPIN with virion 
budding.  In the model proposed in figure 7.5, SNAPIN would likely traffic HIV-1 Gag 
to lysosomes for degradation prior to reaching the plasma membrane.  The finding that 
SNAPIN is known to target cellular proteins to lysosomes for degradation and that 
SNAPIN itself seems to be turned over in lysosomes would support this hypothesis (98).  
This is further supported by Western Blot analysis and subtilisin experiments.    
Anti-p24 Western Blots revealed that there was no difference in the amount of 
intracellular p24/p55 in cell lysates from 293T or COS7 cells co-transfected with 
SNAPIN and wild-type or Vpu-deficient proviral clones.  The absence of a “build up” of 
intracellular viral proteins suggests that SNAPIN expression leads to the degradation of 
Gag.  Perhaps, an experiment in which cellular translation was shutoff (e.g. using 
cyclohexamide) would reveal that in the presence of SNAPIN, the degradation rate of 
intracellular Gag increases.  
The aforementioned hypothesis is supported by previously published studies that 
demonstrated that in Jurkats, which do not express Bst-2, Vpu-deficient particle release is 
reduced compared to wild-type levels; however, intracellular accumulation of viral 
proteins is not observed (97).  Furthermore, subtilisin treatment of Jurkats failed to 
release appreciable amounts of virions as p24 levels were equivalent to Jurkats treated 
with buffer alone.  This is in stark contrast to the current model of Bst-2 antiviral activity 
on particle release (76). 
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Several experiments indicated that the restrictive mode of action of SNAPIN and 
Bst-2 occur at divergent points of viral egress. First, the finding that decreased expression 
of SNAPIN could alleviate some of the restrictive properties associated with HeLa cells 
in the presence of Bst-2 suggests that SNAPIN acts independently of Bst-2.  Second, the 
additive effects observed during experiments in which the combination of siRNAs 
targeting both SNAPIN and Bst-2 resulted in an even greater increase in Vpu-deficient 
virus released suggests that these two cellular factors restrict viral egress at different 
stages.  
 Viral particle release can occur through two distinct pathways; either by directly 
budding through the plasma membrane or through the endosome/exosome pathway (47).  
The pathway used during viral egress appears to be cell type specific.  It has been well 
established that the primary route of viral release in macrophages and dendritic cells is by 
budding into endosomes while in T-cells, budding mainly occurs at the plasma membrane 
(95). However, viral budding in T-cells is not evenly distributed across the plasma 
membrane but occurs specifically at regions with high levels of late endosomal markers 
(also called lipid rafts).  These regions are thought to be sites of immediate exosome 
biogenesis (95, 105, 116, 117).  In support of this conclusion, two previous publications 
have demonstrated that the cellular proteins associated with nascent virions are strikingly 
similar with those found in exosomes, which form at lipid raft regions of the plasma 
membrane (144, 145). 
 Interestingly, the plasma membrane budding of virions in T-cells is not dependent 
on Gag, but on the expression of Vpu (95).  In the absence of Vpu, virion budding occurs 
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primarily into endosomes even in T-cells.  Clearly, Vpu expression alters Gag-trafficking 
prior to reaching the plasma membrane suggesting that the increased viral titers observed 
in the presence of Vpu may actually be due to an alteration in the route of viral egress. 
This hypothesis is supported by a recent finding that suggests that the ability of Vpu to 
promote HIV-1 egress and the ability of Vpu to escape Bst-2’s antiviral activity are two 
independent functions of Vpu (118).  
While preliminary research has suggested that Bst-2 tethers virions at the plasma 
membrane, retention in other intracellular membrane vesicles is certainly possible.  The 
structure of Bst-2 would suggest that any membrane budding may be inhibited by its 
expression including membrane vesicles that bud from the ER or Golgi. This possibility 
is supported by the findings that suggest that the greatest concentration of Bst-2 is found 
in intracellular compartments rather than at the plasma membrane (119, 120).  
At the plasma membrane, Bst-2 specifically localizes to lipid rafts where it is 
presumed to anchor adjacent lipid rafts together (119). Interestingly, Bst-2 is thought to 
traffic between recycling endosomes and the plasma membrane in a clathrin-dependent 
mechanism (120). Since internal Gag-GFP aggregates are observed when clathrin-
mediated endocytosis is inhibited, the role of Bst-2 in the formation of internal aggregates 
is further debatable (121, 122).  Studies to examine the dynamics of exosome production 
in the presence or absence of Bst-2 expression may demonstrate that Bst-2 simply 
prevents membrane budding in general and not solely in the context of viral egress.       
 One interesting piece of evidence that supports the hypothesis that Vpu alters the 
exosome pathway may have been demonstrated inadvertently by Miyagi et al (75).  As 
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shown in figure 7.4, Bst-2 was detected in mock infected supernatants after pelleting 
through a sucrose cushion gradient. While the authors do not specifically comment on 
why Bst-2 is apparently released from mock infected HeLa cells, it is possible that Bst-2 
is being constitutively released from HeLa cells through the production and release of 
exosomes. The detection of Bst-2 in mock samples suggests that Bst-2 must be a 
component of a structure with a high enough density to pellet through a sucrose cushion 
gradient.   
Of particular interest, however, is that Bst-2 seems to be absent from supernatants 
taken from HeLa cells transfected with wild type virus, but not Vpu-deficient proviral 
clones (75).  Since the authors demonstrate that Vpu expression alters the presence of 
Bst-2 in supernatants, a model suggesting that Vpu inhibits exosome release is clearly 
feasible.  Previous studies from several groups demonstrated that HIV-1 is capable of 
diverting the exocytic machinery to reach the plasma membrane (122-126).  
In addition, the likelihood of Bst-2 being a component of exosomes is further 
supported as a recent report determined that Bst-2 could be detected in blood samples of 
patients with certain types of cancers (127, 128).  Since Bst-2 has an N-terminus 
transmembrane region and a C-terminus GPI-anchor, Bst-2 would more than likely be a 
component of a secreted membranous structure if it is found in patient serum (119). 
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Figure 7.4: Bst-2 is detectable in supernatants from mock and Vpu-deficient virus 
infected cells, but not from wild type infected cells. HeLa cells were transfected with 
wild type or Vpu-deficient proviral clones.  After 48 hrs, supernatants were collected and 
virions were pelleted through a two step gradient.  Lanes 1 to 3, analysis of lysates; lanes 
4 to 9, analysis of supernatant pellets.  Bst-2 is detected in supernatant mock infected  and 
Vpu-deficient viral pellets. However, Bst-2 is not detected in wild type pellets (75).  
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 One proponent of the exosome release pathway, Dr. Hildreth, proposed that HIV 
exploits the intracellular vesicular trafficking pathways involved in the biogenesis of 
exosomes in what is known at the Trojan exosome hypothesis (95).  The hypothesis 
predicts that virus particles and exosomes should contain similar lipids and proteins, use 
the same protein trafficking and vesicle biogenesis pathways, and be capable of entering 
neighboring cells in the absence of a retroviral envelope protein (95). While ample 
evidence supporting all three criteria of the Trojan exosome hypothesis is presented, the 
most relevant evidence pertaining to the development of a putative role of SNAPIN in 
inhibiting viral egress entails the examination of the protein trafficking and vesicle 
biogenesis aspect of the hypothesis.   
The early stage in the biogenesis of exosomes involves the formation of 
intralumenal vesicles (ILVs) by inward budding of endosomal membranes (82, 85). ILVs 
are also known as multivesicular bodies (MVBs) and once they form, ILVs can follow 
one of many different paths.   One possible fate for ILVs includes the fusion of 
endosomes harboring ILVs with lysosomes and their subsequent degradation (82, 85).  
Alternatively, MVBs can fuse with the plasma membrane thereby enabling the release of 
ILVs into the extracellular environment as exosomes (82).   
In the context of retroviral budding, the expression of Gag alone is sufficient for 
the production of virus-like particles (129). According to the Trojan exosome hypothesis, 
Gag should therefore be targeted to ILVs.  In general, protein targeting to ILVs may 
occur through several mechanisms including binding to ILV components, fatty acylation, 
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aggregation and monoubiquitination (129, 130).  Interestingly, Gag proteins from many 
retroviruses have been shown to possess these characteristics (95, 129, 130).   
HIV Gag has been shown to interact with components of ILVs and ILV 
biogenesis factors such as cyclophilin and TSG101 (129, 131).  siRNAs targeting specific 
components involved in the biogenesis of ILVs significantly impairs viral production 
(95).  It has also been shown that Gag is N-terminally myristoylated and 
monoubiquitinated and is also capable of forming large intracellular aggregates (95). 
 It has been hypothesized that the presence of Gag in endosomes may facilitate the 
recruitment of ESCRT complexes required for viral egress, the packaging of viral 
genomic RNA and envelope incorporation (82, 85).   In addition, viral egress through 
endosomal pathways may play an important role in polarized budding from infected cells 
and may provide a viral reservoir (95).  Unfortunately, functional assays to determine the 
fate of the endosomal pool of Gag have been relatively limited (122).   
 A recent study, however, examined how endosomal trafficking regulated HIV-1 
biogenesis by using three drugs that inhibit endosomal trafficking at different stages: i) 
monensin, an ionophore that neutralizes acidic intracellular compartment; ii) nocodazole, 
which depolymerizes microtubules and blocks motorized transport; and iii), chloroquine, 
which inhibits late endosome-lysosome fusion (122).   
Human HT1080 cells treated with monensin or chloroquine showed 87 and 97% 
increases in Gag accumulation in late-endosomes by fluorescence microscopy analysis. 
EM analysis demonstrated that in untreated cells, 33% of virions were at the plasma 
membrane while the remaining 67% was observed in intracellular compartments. Notably 
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HT1080 cells do not express Bst-2, and hence, intracellular accumulation of virions 
cannot be attributed to Bst-2-mediated endocytosis of virions attached to the plasma 
membrane (122).  In contrast, cells treated with monensin and chloroquine resulted in 
greater than 91 and 81% accumulation of virions in intracellular compartments, 
respectively. These results suggest that Gag transport through the endosomal pathway is a 
transient and active phase of viral egress (122).  
Importantly, these studies were able to determine that the intracellular vesicles 
containing Gag did not originate from the plasma membrane as they were negative for 
plasma membrane markers (122, 143).  In addition, intracellular vesicles were still 
observed in the presence of a dominant negative form of dynamin.  In general, dynamin 
is required for both clatherin-dependent and cholesterol-dependent endocytosis from the 
plasma membrane, therefore, virion budding likely occurs in endosomal vesicles (122). 
Perhaps the most interesting aspect of these studies was the finding that all three 
drugs enhanced the release of viral particles from cells transfected with Gag.  Treatment 
with monensin resulted in a modest 2-fold increase, while treatment with nocodazole 
increased viral titers by 3-fold.  Impressively, treatment of cells with chloroquine resulted 
in a 7-fold increase in viral titer (122).  More sensitive pulse-chase experiments indicated 
that the addition of chloroquine could generate 20-fold increases in viral titer and that the 
overall amount of Gag in lysates actually decreased compared to untreated cells. 
These results suggest that under normal conditions the majority of newly 
synthesized Gag is targeted for degradation in lysosomes (122). This is in accordance 
with previous studies that demonstrated that only a small fraction of Gag (20%) forms 
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virus particles (132).  The precise mechanisms that are involved in the trafficking of 
newly synthesized Gag to lysosomes are for the most part, unknown.  However, the role 
of one cellular protein in Gag trafficking, TSG101, may suggest a possible link between 
Gag and lysosomal degradation. 
As mentioned previously, TSG101 is required for the facilitation of viral egress 
(134).  TSG101, which is a component of the ESCRT-1 complex, promotes membrane 
alterations within the cell that result in the formation of MVBs (85, 133).  The normal 
cellular function of TSG101 is to transport cellular proteins that are marked for 
degradation, generally by monoubiquitination, to MVBs that eventually fuse with 
lysosomes (82, 142).  Since Gag is monoubiquitinated and interacts with TSG101, 
perhaps Gag enters the same pathway. 
The outcome for the interaction of Gag with TSG101, however, is the production 
and release of virions. It has been proposed that Gag uses TSG101 to gain access to the 
downstream machinery needed for viral budding as opposed to degradation (131, 133). 
Indeed, previous research has demonstrated that HIV-1 accumulates in “nonacidic” 
endosomes in macrophages (135).  Therefore, it is possible that although Gag enters 
MVBs, the end result is not the trafficking of Gag containing MVBs to lysosomes, but 
the cellular components involved in exosome release.   
Since SNAPIN has previously been reported to target cellular proteins to 
lysosomes and has also been implicated in the formation of late endosome-lysosome 
fusion vesicles, perhaps the targeted degradation of SNAPIN by Vpu reduces lysosome- 
mediated degradation of Gag (98).  This would explain why siRNA mediated knockdown 
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of SNAPIN results in increased Vpu-deficient viral titers in Vpu-dependent cell lines. 
This model is further supported by over-expression experiments, which specifically 
reduce Vpu-deficient viral titers. The trafficking of Gag to lysosomes by SNAPIN would 
also explain why intracellular accumulation of Gag is not observed in cell lines with a 
Vpu-dependent phenotype. 
7.3 A Model for SNAPIN mediated-degradation of Gag 
It has been proposed by several researchers that enveloped viruses, including 
HIV, have developed a means for hijacking the endosomal trafficking network to 
promote viral egress (46, 47, 82-86).  In doing so, enveloped viruses have evolved 
mechanisms to take advantage of cellular proteins required for viral assembly, transport 
and abscission from the host’s membrane.  
 Various diverse enveloped viruses such as HIV, Ebola, HBV require the same 
cellular machinery that controls multivesicular body (MVB) formation (84-86, 141).  In 
the absence of viral infection, MVBs play a crucial role in the removal of cellular 
proteins that are targeted for degradation (85-90).  The proper delivery of cellular 
proteins to MVBs relies on specific ubiquitination of the cargo protein, recognition and 
sorting of ubiquitinated cargo to specified endosomal regions, and the formation of and 
scission of cargo filled intralumenal vesicles (85, 87-90).   Intralumenal vesicles and their 
contents are then degraded when MVBs fuse with lysosomes (85, 87-90).  
Topologically, the budding of virions into MVBs or directly at the plasma 
membrane is similar to the budding of intralumenal vesicles (ILVs) that form within 
MVBs (85).  However, the end result in the case of viral infection is not the degradation 
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of virions, but the release of viral progeny into the extracellular milieu.  The mechanisms 
by which enveloped viruses that require the cellular machinery involved in endosomal 
trafficking can usurp the specific stage of MVB-lysosome fusion, are for the most part, 
unknown (82, 83, 91). 
Two previously published reviews have suggested that since several enveloped 
viruses that are thought to use the same cellular trafficking proteins involved in exosome 
formation and release, namely the ESCRT complexes, then ESCRT-dependent viruses 
have likely evolved mechanisms to alter lysosomal sorting pathways (82, 136).   As 
mentioned previously, a substantial percentage of Gag (80%) is indeed targeted for 
degradation by lysosomes (122, 132).   
Furthermore, recent studies have demonstrated that Gag co-localizes to late-
endosomes prior to being transported to the plasma membrane (124). As illustrated in 
figure 7.5, Gag is likely targeted to MVBs via its interaction with TSG101 (step A).  
While it has been speculated that TSG101 traffics Gag directly to the plasma membrane, 
it is likely that Gag would actually enter MVBs in the same manner in which TSG101 
transports other monoubiquitinated cellular factors into MVBs (95).   
Several studies have also shown that Gag co-localizes with both late-endosomal 
and lysosomal markers (95).  Gag has been shown to co-localize with CD63 and 
LAMP2a, which are markers of late-endosomes and lysosomes respectively (124, 135). 
Of particular interest is the observation that the inhibition of Gag-trafficking ultimately 
leads to extensive co-localization of Gag with lysosomal markers (137). 
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Further research has demonstrated that endosomes that are positive for Gag as 
well as viral RNA, are also positive for TiVAMP/VAMP7 (figure 7.5) (122).  TiVAMP 
is a v-SNARE specific for late-endosomes that has been previously implicated in the 
fusion of MVBs with the plasma membrane (88, 125).  Importantly, TiVAMP is also 
necessary for fusion between late endosomes and lysosomes (87). This finding is 
particularly intriguing as TiVAMP likely forms a complex with SNAPIN through its 
interaction with Syntaxin-4 and SNAP23.     
SNAPIN has been shown to form a ternary complex with Syntaxin-4 and 
SNAP23, suggesting that SNAPIN is a component of SNARE-complexes (102).  
Furthermore, Syntaxin-4 and SNAP23 have been shown to interact with TiVamp, 
suggesting that these SNARE-proteins are involved in the exocytosis of late-endosomes 
(138).  However, their interaction with SNAPIN may be involved in the trafficking of 
late-endosomes to lysosomes rather than to the plasma membrane (figure 7.5).  In support 
of this model, SNAP23 and Syntaxin-4 have been implicated in the exocytosis of 
lysosomal contents (138). 
 Interestingly, the same proteomics study that first demonstrated that Vpu may 
target Bst-2 for degradation in HeLa cells also identified Syntaxin-4 as a target for 
degradation by the Kaposi’s Sarcoma herpes virus K5 protein (71).  In addition, an 
independent study determined that HIV-1 Tat induces the expression of a miRNA that 
inhibits SNAP25 expression (the neuronal homolog of SNAP23) (139). Given that two of 
the three members of the ternary complex are known targets of viral proteins, the 
degradation of SNAPIN is likely a relevant function of Vpu. 
124 
 
 
Figure 7.5: A Model of SNAPIN mediated degradation of Gag. In the proposed model 
of the effects of SNAPIN expression on Gag trafficking depicted in figure 7.5, evidence 
suggests that mono-ubiquitinated GAG enters MVBs through its interaction with 
TSG101.  Once Gag is inserted into MVBs, cellular factors target MVBs to the plasma 
membrane through the exosome pathway or to lysosomal compartments for degradation.  
The expression of Vpu, partially inhibits the trafficking of Gag to lysosomes by targeting 
SNAPIN for degradation. The inhibition of transport to lysosomes promotes virus release 
through the exosome pathway.  A variation of the model proposed in the above figure, in 
which plasma membrane associated virions are internalized through endocytosis, 
trafficked to MVBs and sorted to lysosomes or released at the plasma membrane through 
exocytosis pathways, has been previously suggested (144).   
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7.4  Future Considerations 
Although the experiments conducted in this dissertation have identified a 
potentially novel mechanism by which HIV-1 promotes viral production, key 
experiments to support the overall hypothesis are still required.  An alternate model based 
on the observation that Vpu may block the exosome pathway could be attributed to 
previously identified functions of SNAPIN. Since SNAPIN has been shown to have an 
important role in synaptic vesicle fusion and neurotransmitter release at the plasma 
membrane in neurons and is also part of the exocyst complex, perhaps Vpu-mediated 
degradation of SNAPIN may promote virus release by hijacking the later stages of 
exosome biogenesis (93, 167). Clearly, SNAPIN may prevent viral egress by a 
mechanism that is yet to be identified.  
However, it must be noted that several human pathogens that enter endosomal 
compartments, both viral and bacterial, have evolved mechanisms to avert degradation by 
impeding lysosomal function (149).   Interestingly, lysosomal de-regulation has been 
previously reported as a putative cause for apoptosis in HIV-1 infected CD4+ T-cell 
(150).  In addition, microarray analysis of infected dendritic cells revealed that HIV-1 
may further decrease lysosomal activity by down-regulating a specific sub-set of 
lysosomal related genes (151).    
Hence, determining the mechanisms by which SNAPIN reduces viral titers may 
provide additional insights as to how to manipulate a normal cellular process to target 
virions for lysosomal degradation.  Furthermore, previously published findings 
demonstrated that the addition of lysosomal inhibitors to infected cells essentially purged 
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them of intracellular virions (122).  This is especially intriguing as macrophages and 
other cell types have been shown to maintain a viral reservoir for long periods of time 
(24). If intracellular virions can be targeted for lysosomal degradation, perhaps viral 
reservoirs can be eliminated.   
Unfortunately, the current debate as to whether virion budding occurs at the 
plasma membrane versus MVBs, has made interpretation of relevant research in the field 
of HIV egress somewhat obscure. While ample evidence has emerged to support both 
sides of the debate, it is clear that examining viral egress in the context of a physiological 
system is a daunting task.  However, experimental protocols that involve the transfection 
of micrograms of Gag-GFP DNA in cells grown in chamber slides are hardly 
representative of natural infections (106).  The use of this artificial system in these 
experiments was to demonstrate that internal aggregates should not be associated with a 
Vpu-dependent phenotype.  
The appearance of internal Gag-GFP aggregates that appear to co-localize with 
endosomal markers, such as Rab5, likely forms due to a saturation of cellular factors 
required for viral abscission from the plasma membrane (106). Eventually, through the 
process of endocytosis, internal aggregates will likely form as a bi-product of over-
expression. Furthermore, recent publications have demonstrated that the over-expression 
of Gag-GFP is uniform throughout the plasma membrane (106, 113).  This is in stark 
contrast with the current model that proposes that virions are released at the lipid raft 
regions of the plasma membrane (95, 140).  Further research into this ‘grey’ area of the 
viral life cycle is clearly required.  
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The down-regulation of Syntaxin 4 and SNAP25 by Herpes virus K5 protein and 
HIV Tat, in addition to Vpu-mediated degradation of SNAPIN, suggests that the 
inhibition of this ternary complex is important for viral replication (71, 139).  
Interestingly, the same study that identified a miRNA that reduces SNAP25 expression 
also identified a miRNA that could potentially target SNAP23 (139).  Further 
experimentation is required to determine the normal cellular functions of these proteins 
and their implications in the viral life cycle and may help define why divergent viruses 
appear to target members of this complex for degradation.   
These experiments, as well as recent publications, have demonstrated that the 
extent of the Vpu-phenotype observed when Bst-2 is ectopically expressed in normally 
permissive cell lines is more moderate than previously reported (79, 80).  In all 
likelihood, Bst-2 is a component of the IFN-response that inhibits the release of 
enveloped viruses in general (81).  The expression of Vpu by wild type HIV-1 has a 
moderate positive effect on viral production in the presence of endogenous Bst-2 in 
various cell lines tested.  As previously suggested, the effect may be due to the altered 
trafficking of Gag when Vpu is expressed.  Interestingly, a recent report has suggested 
that Vpu may rescue viral egress by different means in lymphoid cells as opposed to 
macrophages (157). 
Clearly, since little to no Bst-2 is expressed in cell types normally associated with 
HIV-1 infection, further efforts to identify additional cellular factors involved in the Vpu-
phenotype is needed (75, 100, 148).  One such factor, CAMLG, which was identified 
during these yeast two-hybrid and HeLa-shRNA screens has recently been published 
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(100).  However, since Bst-2 was identified, CAMLG has been for the most part 
considered obsolete (146, 147).  While CAMLG is not nearly as potent as Bst-2 or 
SNAPIN, a Vpu-dependent phenotype was observed during these studies.  This suggests 
that the Vpu-phenotype cannot be attributed to a single cellular factor.  More than likely, 
the cell type dictates what cellular factors are involved in the Vpu-phenotype.  
 The finding that Vpu-mediated degradation of SNAPIN can be inhibited using 
either proteasome or lysosomal inhibitors suggests that two populations of SNAPIN 
molecules exist.  The first population of SNAPIN is targeted for proteasome degradation 
by Vpu in the ER prior to its translocation to late-endosomes /lysosomal vesicles, while 
the second population of SNAPIN is targeted for degradation in lysosomes.  Interestingly, 
recent studies in HeLa cells demonstrated that both proteasome and lysosomal inhibitors 
could prevent Bst-2 degradation (152-155).  This suggests that Vpu can target the same 
cellular factor for degradation using two independent degradation pathways.  Further 
analysis of the mechanisms involved in Vpu-mediated degradation of SNAPIN are also 
required and may provide useful insights into previously unknown functions of Vpu.   
While it is clearly evident that Vpu specifically targets SNAPIN for degradation, 
the effects of SNAPIN on viral production proposed in figure 7.5 are, for the most part, 
speculative.  Nonetheless, a significant correlation does appear to exist in the context of 
SNAPIN expression levels and the Vpu-dependent phenotype.  Understanding and 
identifying cellular factors that traffic Gag to lysosomes may provide a new area for the 
development of antivirals.  If a correlation between SNAPIN expression and Gag 
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degradation through lysosomes can be established, perhaps preventing Vpu-mediated 
degradation of SNAPIN may reduce viral loads in HIV positive patients. 
It is hoped that future research on SNAPIN may unlock some of the unknowns 
associated with the late stages of viral replication and that potentially, novel therapeutic 
targets may be identified.   
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Appendix I 
 
 
 
 
 
 
 
 
 
 
Results from additional shRNA cell lines. The shRNA targets represented in the above 
graph were identified by yeast two-hyrbid screening. The shRNA targets in these HeLa 
shRNA cell lines resulted in an overall reduction of wild type virus and/or did not 
positively affect Vpu-deficient viral titers in comparison to wild type virus titers. Viral 
titers were determined by p24 ELISA at the indicated time points.  Average of triplicate 
sample is represented on graph.  
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